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Assessment of Overall Survival, Quality of Life,
and Safety Benefits AssociatedWith New CancerMedicines
Sebastian Salas-Vega, MSc; Othon Iliopoulos, MD; Elias Mossialos, MD, PhD
IMPORTANCE There is a dearth of evidence examining the impact of newly licensed cancer
medicines on therapy. This information could otherwise support clinical practice, and
promote value-based decision-making in the cancer drugmarket.
OBJECTIVE To evaluate the comparative therapeutic value of all new cancer medicines
approved by the US Food and Drug Administration (FDA) and the EuropeanMedicines
Agency (EMA) between 2003 and 2013.
DESIGN, SETTING, AND PARTICIPANTS Weused a narrative synthesis approach to
systematically synthesize and analyze English, French, and Australian health technology
assessments (HTAs) of all new cancer medicines licensed in the United States and Europe
between 2003 and 2013.
INTERVENTIONS Sixty-two newmolecular entities with a primary oncology indication.
MAIN OUTCOMES ANDMEASURES Overall survival (OS), quality of life (QoL), and safety.
RESULTS Of the 62 new active cancer molecules approved by the FDA and EMA between
2003 and 2013, 53 were appraised by English, French, or Australian HTA agencies through
May 2015. Of these 53 drugs, 23 (43%) increased OS by 3months or longer, 6 (11%) by less
than 3months, and 8 (15%) by an unknownmagnitude; there was no evidence to suggest
that the remaining 16 (30%) increased OS over best alternative treatments. Where overall
survival gains could be quantified, all new cancer drugs were associated with a mean (SE)
total increase in OS of 3.43 (0.63) months over the treatments that were available in 2003.
Drug-related improvements in OS were, however, widely distributed across therapeutic
targets—ranging between 0 (thyroid, ascites) and 8.48months (breast cancers)—and were
sometimes based onmodeled data, indirect or nonactive comparisons, or nonvalidated
evidence. Although 22 (42%) of 53 newmedicines were associated with an increase in QoL,
24 (45%) were also associated with reduced patient safety. Of the 53 new cancer drugs, 42
(79%) were associated with at least some improvement in OS, QoL, or safety.
CONCLUSIONS AND RELEVANCE Although innovation in the oncology drugmarket has
contributed to improvements in therapy, the magnitude and dimension of clinical benefits
vary widely, and there may be reasons to doubt that claims of efficacy reflect real-world
effectiveness exactly. These findings raise important questions for clinical decision-making
and value-based policy.
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T herearegrowingquestionsabout thevaluegained fromspendingonwhat seem tobe evermore expensive can-cer medicines. Rising expenditures may make it diffi-
cult for patients to access or remain compliant with life-
extending therapies.1,2 Yet, somehave argued that highprices
may be justified if new and innovative treatments offer sig-
nificant benefits to patients.2,3 Even as studies point to gains
inoverall survival (OS) from innovative cancermedicines,4 ef-
forts to examine thevalue fromspendingonnewcancerdrugs
remain stymied by a dearth of systematic evidence on their
clinical risks and benefits. This lack of evidence makes it dif-
ficult for the public to demand more from innovation,5 and,
where costs factor into the decision-making process, for cli-
nicians and patients to balance preferences for the expected
impact of treatment against rising drug expenditures.
One difficulty in characterizing the clinical impact of
new cancer drugs is the multiplicity of outcome measures.
Overall survival has traditionally been taken as the gold
standard among oncology efficacy endpoints.6,7 The United
States Food and Drug Administration (FDA), for its part, des-
ignates OS as the only “universally accepted” and the “most
reliable” direct measure of benefit in oncology drug trials.8
The European Medicines Agency (EMA) similarly states that
convincing favorable effects on OS are, from a clinical and
methodological perspective, the “most persuasive outcome”
of oncology trials.9 As policymakers adopt new regulations
to expedite access to medicines for serious conditions,10,11
interest has grown in measuring effectiveness through sur-
rogate markers.12 These, however, are not yet systematically
measured by regulators8,13 and still have inconsistent or
uncertain predictive clinical value.14,15 Despite its potential
limitations, the American Society for Clinical Oncology’s
(ASCO) recently published16 Value Framework in fact
recommends that efficacy benefits be measured through
progression-free survival or response rates only if OS is not
reported.17 In addition to efficacy measures, quality of life
(QoL) and safety are also used by regulators and clinicians to
fully consider the impact on how patients feel and function
owing to treatment.17-19
To shed light on the clinical risks and benefits from new
cancer drugs, this study took a narrative synthesis approach
to review regulatory assessments of the impact on OS, QoL,
and safety fromall cancermedicines newly licensed in theUS
and Europe over the past decade. Since US licensing deci-
sionsdonot requireproofof comparativeefficacyandmaynot
consider OS benefits under accelerated licensing
procedures,20,21weextracted and reviewed summary conclu-
sions of drug-related OS, QoL, and safety benefits from Eng-
lish (The National Institute for Health and Care Excellence,
NICE), French (HauteAutorité de Santé, HAS), andAustralian
(Pharmaceutical Benefits Advisory Committee, PBAC) health
technology assessment (HTA) agencies. We find that OS ben-
efits varywidely, improvements in OS andQoL often come at
the costof safety, and thereare reasons todoubtwhether clini-
calefficacyhasbeenmatchedbyeffectiveness in therealworld.
This studyprovidesadditional clarityon thepotential risksand
benefitsofnewcancermedicines. It also raisesquestionsabout
howclinical impact ismeasuredby regulators, how the scien-
tific evidence isused to informclinicalpractice, andhowmuch
value is generated from cancer drug spending.
Methods
Inclusion and Exclusion Criteria
All new molecular entities (NMEs) approved by the FDA and
EMAbetween2003and2013with aprimary indication for on-
cology were eligible for inclusion. This study focused exclu-
sively on primary indications,which are likely to reflectmain
intendeduse.Drug inclusion criteriawere adapted fromapre-
vious study by Roberts et al.22 Because this study did not use
or access patient-level data the London School of Economics
andPolitical Sciencedetermined that ethical approvalwasnot
required.
Drug Appraisals
Evaluations of the clinical impact of new cancer drugs were
obtained from English, French, and Australian agency HTAs
published through May 2015. These agencies regularly pub-
lish HTAs in the English language, and are required to evalu-
ate the clinical impact of new medicines in relation to exist-
ing standards of treatment thatwouldmost likely be replaced
by the new intervention.23-25 Health technology assessments
were selected for review if they pertained to the same target
condition as the first FDA-approved indication. Ifmultiple re-
ports evaluated the same target condition,we selected the lat-
est report that most closely matched the first FDA-approved
indicationwith respect to any treatment restrictions (eg, can-
cer staging). In ambiguous cases, determinations were made
in consultation with a medical expert. Initial EMA-approved
indications were used if the drug had not been approved by
US regulators through May 2015.
Data Extraction and Synthesis
Two reviewers (S.S.V. andR.L.) adapted thepatient, interven-
tion, comparator, outcomes framework26 to independently re-
view assessments of the clinical impact of new cancer medi-
cines. Informationonrecommendedpatientpopulations,novel
interventions, and therapeutic comparators were extracted
Key Points
Question What are the overall survival, quality of life, and safety
benefits of recently licensed cancer medicines?
Findings An analysis of health technology assessment reports
found that new cancer drugs were associated with increased
overall survival by an average of 3.43months between 2003 and
2013, with 43% increasing overall survival by 3months or longer,
11% by less than 3months and 30%were not associated with an
increase in overall survival. Most new cancer drugs improved
quality of life, and were associated with reduced patient safety.
Meaning The added benefits of new cancer medicines vary
widely across and within therapeutic indications andmay be based
onmodeled data, indirect or nonactive comparisons, or
nonvalidated evidence.
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from each drug appraisal, as were evaluations of the impact
on OS, QoL, and safety of drug treatment. The Table lists the
classes of evidence that were typically evaluated and re-
ported by English, French, and Australian authorities to as-
sess OS, QoL, and safety. This approach captured key out-
come measures that are regularly considered during formal
drug reviews,8,18,19 and reflected ASCO’s recently published
conceptual framework formeasuring thevalueof cancer treat-
ment options.17
A rules-based process was undertaken to evaluate evi-
dence reportedbyHTAagencies. For this,weconsideredover-
all judgments of the available evidenceonOS,QoL, and safety
from HTA summary sections, their acknowledgement of the
significance of clinical trial results, or referral to prior evalu-
ations of the primary evidence. If these were absent, or if an
HTA agency concluded that clinical benefits could not be as-
sessed, corresponding extraction parametersweremarked as
missing.Disagreements onhow to interpretHTAagency sum-
maries about the clinical impact of treatment were resolved
through consensus. Overall survival benefits were catego-
rized as 3 months or longer, less than 3 months, increase but
of unknownmagnitude, and no demonstrated increase. A re-
cent ASCO working group has suggested that improvements
in median OS of at least 20% may demonstrate a clinically
meaningful improvement in survival. However, our ap-
proachwasdesignedto reflect thesystemthat is currentlyused
inEngland to identifyOS improvements that are large enough
to justify additional expense in end-of-life care,27 andused at
times by Australian authorities to assess new health
technologies.28 Quality of life and safety benefits were cat-
egorized as improvement, reduction, mixed evidence, or no
difference relative to the standards of care existing at time of
evaluation. A hierarchical process was followed to generate a
compositemeasure of thedrug-related effect onOS,QoL, and
safety. In instances where assessments were available from
multipleHTAagencies, this involved identifying themostposi-
tivedrug-relatedsurvivalbenefit to representwhatmaybepos-
sible from treatment. For QoL and safety, if 1 HTA agency in-
dicated that the newmedicinewas associatedwith an overall
improvement in therapy,butanother foundnochange,weclas-
sified thedrugasproducinganetpositivegain. If opposingevi-
dence existed,we classified the drug as being associatedwith
mixed evidence. Please see the eMethods section in the
Supplement for additional information. Defining features of
each drug appraisal were also recorded, and a physician clas-
sified all eligible drugs into therapeutic target groups accord-
ing to their FDA-approved primary indication. A summary of
drug-related effects on OS, QoL, and safety is provided in
eTable 1 in the Supplement, and an overview of the regula-
tory evidence used in our analysis is provided in eTable 2 in
the Supplement.
Descriptive statistics were used to summarize composite
measures of the impact on OS, QoL, and safety of all medi-
cines included in this analysis.Krippendorff’sαcoefficientwas
used tomeasure the level of agreement amongHTAagencyas-
sessments of the clinical benefits of treatment, and to inform
our interpretation of results.29 Because reliability standards
should relate to local requirements,30our interpretationof this
statistic focuses on the difference between coefficients. For
convenience, however, we take an α level of .67 or greater to
Table. Evidence Generally Reported by HTAAgencies to Evaluate
Drug-Related Effects on Key OutcomeMeasures
Outcome
Measure Evidence
OS Median OSa,b,c
Mean OSa,c
Survival probability (%)b,c
OS (mean/median, NOS)b,c
Expectations of impact on mortality (NOS)b
QoL Symptom improvementa,b
Time to change (deterioration/improvement) in functioning
or symptomsa,b,c
QoL instrumentsa,b,c,d
Impact on utilitya
Expectations of impact on QoL (NOS)a,b,c,e
Patient representative/clinical expert inputsa,b,f
Safety Incidence of AEa,b,c,g
Incidence of severe or serious AEa,b,c,h
Time to first AE (≥grade 3)a
Treatment discontinuation or dose reductiona,b,c
Overall tolerance and safety profile (NOS)a,b,c,i
Treatment-related deathsa,b,c,j
Patient representative/clinical expert inputsa,b,c,k
Abbreviations: AE, adverse events; HTA, health technology appraisal; NOS, not
otherwise specified; OS, overall survival; QoL, quality of life.
a The National Institute for Health and Care Excellence.
bHaute Autorité de Santé.
c Pharmaceutical Benefits Advisory Committee.
d For example, Functional Assessment of Cancer Therapy-Anemia (FACT-An)
questionnaire, TimeWithout Symptoms and Toxicity (TwiST) and
Quality-Adjusted Survival and Toxicity (Q-TwiST); Short FormHealth
Survey-Version 2.0 (SF12 v2), EQ-5D and EuroQol-5 Dimensions-Visual
Analogue Scale (EQ-5D-VAS); Functional Assessment of Cancer
Therapy-General (FACT-G); Brief Pain Inventory-Short Form (BPI-SF);
Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym); Functional
Assessment for Cancer Therapy–Kidney Symptom Index-Disease Related
Symptoms (FKSI-DRS); Functional Assessment for Cancer Therapy–Kidney
Symptom Index-15-Item (FKSI-15); Functional Assessment of Cancer
Therapy-Prostate (FACT-P); EORTC Core Quality of Life Questionnaire
(QLQ-C30); EORTCMultiple MyelomaModule (QLQ-MY20); Cancer
Treatment Satisfaction Questionnaire (CTSQ); Karnofsky performance status;
Eastern Cooperative Oncology Group (ECOG) performance status; Lung
Cancer Symptom Scale (LCSS).
e Internal HTA agency opinion or expectation regarding aspects of clinical
impact, not directly informed by the available evidence.
f May include inputs on preference for oral or intravenous administration,
amount of time in hospital, number of hospitalizations, meaningfulness of
improvements in symptoms (eg, fatigue, pain), and ability to perform daily
activities.
g Described as adverse events (NOS), treatment-emergent adverse events
(TEAEs) without specification of serious grade, grades 1/2 adverse events,
adverse events of mild to moderate intensity
hDescribed as serious adverse events (SAEs), grades 3/4 adverse events,
treatment-related syndromes (eg, systemic inflammatory response syndrome)
i For example, discussion of overall tolerance and safety profile without
reporting of primary evidence in assessment.
j Including grade 5 adverse events.
k Examples of inputs from patients, patient representatives, or clinical experts
included comments on patient willingness to accept adverse effects given the
benefits of treatment, and comparability of adverse reaction profiles.
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indicate a high level of agreement.30 Finally, to attempt to ex-
ternally validate our results, we sought informal feedback on
our analysis from 2medical experts from the FDA. After pro-
vidingtheir informedconsent toparticipateanonymously,both
experts were given a written description of our methods and
a copy of all results. They were asked to review all materials
andprovide feedback as towhether our synthesiswas consis-
tent with their own perception of the impact from new can-
cer medicines on clinical therapy in the United States. Please
see the eMethods section in the Supplement for further de-
tails on our methodology as well as a discussion of potential
limitations.
Results
A total of 62newactive cancermoleculeswere eligible for this
study (Figure 1), 4 ofwhichwere approvedby theEMAbutnot
the FDA through May, 2015. Molecule descriptors are pro-
vided in eTable 2 in the Supplement. Of those 62 drugs, 53
(85%) were assessed for OS by at least 1 of the 3 international
HTA agencies considered through May, 2015. The remaining
9 molecules may have been evaluated after our study end-
date, not have been reviewed by HTA agencies if considered
low-priority,33 ormay have been rejected by European (EMA)
or national licensing authorities. Of the 53 drugs thatwere in-
cluded in this study, 35 drugswere assessed by all 3 agencies,
7were assessedby2, and 11were assessedby 1 agency. Inmost
cases, HTA agency assessments were based on the same set
of comparators (eTable 2 in the Supplement).
Overall Survival
Of the 53 drugs that were evaluated, 23 (43%) were con-
firmed by at least 1 HTA agency to increase OS by at least 3
months, though an exact magnitude of increase could not be
estimatedbyHTAagencies for6of these23medicines.Six (11%)
of the53drugs increasedOSby less than3months, and8 (15%)
produced an increase in OS of unknown magnitude. The re-
maining 16 (30%) cancer drugs did not demonstrate an in-
crease inOSover alternative treatments, eitherbecausenodif-
ferencewas foundorbecauseadeterminationwasnotor could
not bemadebyHTAagencies on the basis of the available evi-
dence (eTable 1 in the Supplement).
We examined total gains in OSmade over the last decade
by mapping new interventions against the treatment com-
parators that would be replaced, as identified in HTAs
(Figure2). In all caseswhereOSgains couldbequantified,new
cancer drugs produced a total mean (SE) improvement in OS
Figure 1. FlowDiagramof ReviewProcess
36 Initial approvals 2003-2010
Criteria:
1. Initial approval (NME)
2. Primary oncology
2 Criterion #2
34 Initial cancer approvals 2003-2010
tositumomab; bortezomib; cetuximab; pemetrexed isodium; bevacizumab; 
azacitidine; clofarabine; erlotinib hydrochloride; lenalidomide; nelarabine; 
sorafenib tosylate; sunitinib malate; decitabine; dasatinib; panitumumab; 
vorinostat; lapatinib ditosylate; nilotinib hydrochloride monohydrate; temsirolimus; 
sipuleucel-t; ixabepilone; bendamustine hydrochloride; degarelix acetate; 
everolimus; pazopanib hydrochloride; romidepsin; ofatumumab; pralatrexate; 
eribulin mesylate; cabazitaxel; gefitinib; vinflunine (EMA); trabectedin (EMA); 
catumaxomab (EMA)
22 Criterion #1
31 Initial approvals 2011
Criteria:
1. Initial approval (NME)
9 Initial cancer approvals 2011
asparaginase erwinia chrysanthemi; ruxolitinib; crizotinib; brentuximab vedotin; 
vemurafenib; abiraterone acetate; vandetanib; ipilimumab; 
tegafur/gimeracil/oteracil (EMA)
39 Initial approvals 2012
Criteria:
1. Initial approval (NME)
11 Initial cancer approvals 2012
axitinib; vismodegib; pertuzumab; carfilzomib; zivaflibercept; enzalutamide; 
bosutinib;regorafenib; omacetaxine mepesuccinate; cabozantinib;ponatinib
26 Criterion #1 2 Criterion #2
18 Criterion #1 1 Criterion #2
27 Initial approvals 2013
Criteria:
1. Initial approval (NME)
8 Initial cancer approvals 2013
pomalidomide; ado-trastuzumab emtansine; radium Ra 223 dichloride; dabrafenib; 
trametinib; afatinib; obinutuzumab; ibrutinib
Flow diagram depicting the process used to systematically identify all initial US
Food and Drug Administration approvals occurring between 2003 and 2013 for
molecules with an active primary indication for cancer. Exclusion criterion #1
identifies all molecules that are neither used in oncology, nor indicated as an
active treatment for cancer. Exclusion criterion #2 identifies all molecules that
are used in oncology, but are not indicated as an active treatment for cancer.
Food and Drug Administration initial approvals identified through Roberts et
al22 and Drugs@FDA registry.31 EuropeanMedicines Agency initial approvals
identified through the EuropeanMedicines Agency’s European public
assessment reports search engine.32
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of3.43 (0.63)months (or0.29 [0.05]years) relative to the treat-
ments that were available in 2003. These benefits, however,
varied across andwithin different classes of therapeutics. For
instance, drugs indicated for thyroid cancers produced an av-
erage (SE) increment of 0 (0) months in OS; ascites, 0 (0)
months; lung cancers, 2.09 (0.75)months; hematological can-
cers, 2.61 (1.69) months; gastrointestinal cancers, 2.90 (1.12)
months;prostatecancers,3.17 (0.69)months; skincancers,4.65
(1.05) months; renal cancers, 6.27 (1.92) months; and breast
cancers, 8.48 (3.84) months.
For drugs thatwere assessedby all 3 agencies, English au-
thoritiesweremost likely to attribute significantOS improve-
ments to new medicines, while Australian authorities were
least likely to do so (eFigure 1 in the Supplement). Across the
entire sample, Krippendorff’s α was 0.38, suggesting a low to
moderate level of agreement in assessments of OS benefits
Figure 2. Analysis of Improvements in Overall Survival
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Skin
dacarbazine
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Hematological
chlorambucil
chlorambucil
chlorambucil
high-dose dexamethasone
placebo
conventional care
conventional care
multi-agent salvage
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bendamustine
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clofarabine
dasatinib
nilotinib
nelarabine
BSC
BSC
BSC
BSC vinflunine
Bladder
ado-trastuzumab emtansine
Breast
capecitabine lapatinib
trastuzumab + docetaxel pertuzumab
eribulinTPC
afatinib
trametinib
NEponatinib
Development of new cancer medicines (2003-2013), mapped according to
therapeutic comparator used by health technology appraisal agencies in
appraisal documents to assess therapeutic value. “First generation” drugs are
the set of comparators not approved between 2003 and 2013, whereas “third
generation” drugs are those that were evaluated against medications that were
newly licensed in the study period (“second generation”). Pemetrexeda
represents use for a nonprimary indication—it is therefore considered
independently of the pemetrexed indication that is evaluated in this study.
Survival benefits associated with parallel treatment pathways
(afatinib-erlotinib/gefitinib; ponatinib-nilotinib/dasatinib) are considered
independently of each other, as are those associated with multiple primary
indications (sunitinib). The gain in overall survival (OS) relative to initial
standards of care, for all drugs where marginal increases in OS could be
quantified, is provided with the use of bars that represent the number of
months gained (rounded to nearest integer). If a range of values corresponding
to OS benefits were available across health technology appraisal agencies, an
average was taken. Uncertain increase in OS is represented with a “+”; NE
indicates no established increase in OS.
Overall Survival, Quality of Life, and Safety Benefits FromNew Cancer Medicines Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology Published online December 29, 2016 E5
Downloaded From: http://jamanetwork.com/ by a Harvard University User  on 01/04/2017
Copyright 2016 American Medical Association. All rights reserved.
among all 3HTAagencies (eTable 3 in the Supplement). Inter-
agency agreementwas, however, higherwhen English evalu-
ations were excluded and for the set of drugs that produced
marginal to no improvement in OS (eTable 3 in the Supple-
ment). This may suggest that regulators become increasingly
uncertain about claimsofdrug-related survival benefits as the
magnitude of those claims increases.
Indeed, HTA agency conclusions for 10 of the 23 drugs
that were deemed to increase OS by 3 months or more (ax-
itinib, bosutinib, crizotinib, everolimus, panitumumab,
pazopanib, pomalidomide, sorafenib, sunitinib, and trabec-
tedin) were based on modeled data, indirect comparisons,
or agency opinions. For 5 of the 23 drugs (axitinib, crizo-
tinib, enzalutamide, panitumumab, and pazopanib), signifi-
cant OS benefits were also found relative to 1 treatment
comparator, but were not established in relation to other
possible comparators.
Quality of Life
Of the 53 drugs that were evaluated by at least 1 HTA agency,
22 (42%) improved QoL, 2 (4%) reduced QoL, 1 (2%) was as-
sociated with mixed evidence, and 28 (53%) did not demon-
strate a difference in QoL relative to best alternative treat-
ments (eTable 1 in the Supplement).
As for OS, England’s HTA agency was most likely to find
that newcancer drugs improvedQoL (eFigure 1 in the Supple-
ment). Across the entire sample, therewas amoderate tohigh
level of agreement among HTA agencies in the assessed level
ofQoLbenefit fromnewcancer drugs (α, 0.61) (eTable 3 in the
Supplement). This suggests that HTA agencies tend to simi-
larly interpret the QoL evidence—more so than that of OS—
and lends confidence to the notion that new cancer drugs are
providing QoL benefits to patients.
Still, not all regulatory opinionswere basedon robust evi-
dence. Of the 22 drugs that were deemed to improve QoL,
evaluations for 17 were based on a review of empirical evi-
dence, includingdata fromvalidatedQoLinstruments.TheQoL
benefits associatedwith the remaining 5 drugs (pertuzumab,
trametinib, ziv-aflibercept, sipuleucel-T, and vemurafenib)
were based exclusively on testimony from patient represen-
tatives and clinical experts.
Safety
Eight (15%) of the 53 drugs that were evaluated by HTA agen-
cies were found to improve safety. A far larger share (24, or
45%), however, reduced patient safety. Ten (19%) were asso-
ciatedwithmixed evidence and 11 (21%) did not demonstrate
any difference in safety compared with alternative treat-
ments (eTable 1 in the Supplement).
Mirroring earlier trends forOS, English andAustralian au-
thoritieswere least andmost likely todetermine thatnewcan-
cer drugs reducedpatient safety, respectively (eFigure 1 in the
Supplement). Across the entire sample, there was a low level
of agreement between HTA agencies on the impact on safety
fromnewcancermedicines.Thiswashoweverdrivenbya lack
of consensuswithAustralia’sHTAagency: interagency agree-
mentwasmoderate tohighwhen limited toEnglishandFrench
assessments (eTable 3 in the Supplement).
Clinical Benefits of Treatment
Of the 23 drugs that significantly increased OS by at least 3
months, 15 (65%) were also found to improve QoL, while the
remaining 8 (35%) produced no measurable change. In con-
trast, of the 23 drugs that significantly extended OS, 5 (22%)
improved safety, 11 (48%) reduced safety, 5 (22%) were asso-
ciated with mixed evidence, and 2 (9%) produced no differ-
ence in safety relative to existing standards of care. Most
new cancer medicines that significantly extend life there-
fore also improve QoL, but reduce patient safety (eTable 1 in
the Supplement).
There was a noticeably smaller improvement in QoL in
the drugs that produced marginal to no improvement in OS.
Of the 30 evaluated drugs that did not increase OS by at
least 3 months, 7 (23%) were found to improve QoL, 2 (7%)
worsened QoL, 1 (3%) had a mixed effect, and 20 (67%) were
not associated with any effect on QoL. Safety nevertheless
remained a concern. Of the 30 drugs that did not increase
OS by at least 3 months, 3 (10%) were classified as improv-
ing safety, 13 (43%) reduced patient safety, 5 (17%) were
associated with mixed evidence; the remaining 9 (30%) did
not demonstrate any difference in safety over alternative
treatments.
Across the entire sample, 42 of the 53 new cancer medi-
cines (79%) licensed in the United States and the European
Union between 2003 and 2013, and evaluated by English,
French, and Australian HTA agencies, demonstrated at least
some evidence of an OS, QoL, or safety benefit. These
results were supported by the feedback that we received
from 2 medical experts from the FDA, both of whom gener-
ally agreed with the results that were obtained. One—an
oncologist—stated that the results summarized in eTable 1
in the Supplement were “in line with [his personal] percep-
tions” of the added clinical benefits of the new cancer
medicines.
Discussion
All new cancer drugs licensed between 2003 and 2013 by
the FDA and EMA extended OS by an mean (SE) of 3.43
(0.63) months (0.29 [0.05] years) over the treatments that
were available in 2003. This figure is based on regulatory
assessments and is consistent with those reported by simi-
lar studies.34
While perhaps modest, this OS benefit represents an im-
portant step forward for patients and society, as even minor
improvements in survival canhaveaneffect on reducingmor-
tality at thepopulation level. It is encouraging to therefore find
thatmostnewcancerdrugswereassociatedwith someknown
(55%) or at least unknown (70%) OS benefit, with the largest
share (43%) extending life by an amount that English and
Australian regulators consider to be clinically meaningful
(≥3 months).
To our knowledge, this analysis is the first to take a sys-
tematic approach to evaluate the OS, QoL, and safety ben-
efits associated with new cancer drugs. Our findings indi-
cate that most newly approved cancer medicines (79%)
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increased OS by some known or unknown magnitude, or
demonstrated at least some evidence of improved QoL or
safety over alternative treatments. In general, innovation in
the oncology drug market therefore appears to be bringing
real value to patients and society.
There was evidence to suggest that these benefits are
also concentrated in particular classes of therapeutics. Ten
immunologic drugs were present in our sample, most of
which function by antigenic targeting of cancer cells. Ipili-
mumab was the only drug of a novel class of immunomodu-
lating agents, the immune checkpoint modulators. With the
exception of bevacizumab—which elicits an antiangiogenic
response—immunologic drugs were, on average, better at
extending OS compared to nonimmunologic drugs (5.02 vs
2.30 months). However, this was not true of all immuno-
logic drugs. Perhaps owing to a limited sample size, statisti-
cal testing also showed that this group difference was non-
significant, and that there was no greater effect on quality of
life or safety (data not shown). Ipilimumab was itself associ-
ated with a marginally larger OS benefit (5.7 months).
Future studies may adapt our methodology to examine the
efficacy of the newer immune checkpoint modulators, such
as nivolumab and pembrolizumab.
Thoughperhapspromising, findings fromthisstudyshould
be interpretedwith caution. To validly draw inference on the
impact fromnew immunologic drugs and other cancer thera-
peutics, thisanalysis shouldberepeatedas thenumberofavail-
ablemoleculesgrows.Across theentire sample, regulatoryevi-
dence is sometimes based on modeled data, nonvalidated
inputs, or comparisons against nontargeted or older active
treatments (eg,BSC, chlorambucil), though thismayreflect the
state of clinical practice. Even if these issues are ignored, in-
teragencyagreementondrug-relatedOSbenefits decreases as
the level of benefit increases, indicating that there may be
greateruncertaintyabout thevalue fromnewcancerdrugs that
claim to bring the greatest health benefit. And, as shownwith
frequentlycontrastingEnglishandAustralianassessments, the
regulatory milieu seems to shape the interpretation of evi-
denceontheclinical impact fromnewcancermedicines.These
findings raise important questions about how clinical ben-
efits aremeasured andused to informevidence-basedpolicy,
and they give reason to adapt treatment guidelines to the
unique circumstances and preferences of the patient.
Regulators nevertheless often have the authority to re-
quire submission of all applicable clinical data that is "neces-
sary to address the remit and scope of the technology
appraisal."35 To estimate the clinical value of new medicines
in the absence of real-world observational data, the approach
used in this study may therefore be preferable to secondary
reviews of the published scientific literature.
Still, technological assessments may not always accu-
rately reflect the full extent of clinical risks and benefits that
are observed in practice. For instance, as is the case forKRAS
expression incoloncancer,particulargenomicprofilesarenow
known to predict OS benefits. In part for this reason, gene ex-
pression profiling is increasingly recommended as a tool to
guide chemotherapy decisions.36,37 Sincemany new antican-
cer drugs target proteins that are downstream of genes with
driver somatic mutations,36 any misapprehension about the
geneticmediatorsofdiseasemayprevent regulators fromfully
appreciating their clinical value. Validated biomarkers in fact
often do not exist to guide the selection of patients in clinical
trials who would most likely benefit from treatment.5 Clini-
cal practicemay instead incorporate new evidence on the ge-
netic predictors of response as and when it develops,36 en-
abling personalized and cost-efficient care that optimizes
patientoutcomes.Tobetter reveal the real-worldbenefits from
new cancer medicines, future studies should therefore peri-
odically repeat this analysis with postmarketing,38 observa-
tional or pragmatic clinical trial evidence. The National Can-
cer Institute’s upcoming National Cancer Knowledge System
may provide crucial insights in this regard.
As it stands, 1 in3 (30%)ofallnewlyapprovedcancermedi-
cines arenot associatedwith anyOSbenefit,while 1 in 5 (20%)
neither extend life nor improve QoL or safety. While perhaps
reflectiveofnonactivecomparisons, theapprovalofnewmedi-
cines for orphan indicationswithno alternative treatment, or
the growing use of surrogate efficacy endpoints during regu-
latory evaluations,12 these findings suggest that expendi-
tures for up to 1 out of every 5 new cancer drugsmay be spent
without any OS, QoL, or safety benefit to the patient.
In the short term, these findingshelp to informclinical de-
cision-making by patients and clinicians who, in personaliz-
ing treatment, may have to consider the economic implica-
tions of drug prescriptions alongside individual preferences
for treatment-related risks and benefits. This may be true for
US cancer patients, who typically shoulder high amounts of
cost-sharing, but also if public health systems (eg, England’s
NHS)donotpublicly reimburse fornewcancermedicines.Over
the longer term, efforts should be made to develop evidence
onmechanisms toweight clinical outcomemeasures accord-
ing to their value topatients, and to align these initiativeswith
the regulatory review process.
Thesefindingsraiseanumberof importantquestionsabout
value-for-money inoncology.Wefindthat there is in factawide
distribution in the therapeutic benefits associated with re-
centcancerdrug innovations, suggestingasimilarlywidevaria-
tion in the value that they bring to society. Somemedications
(eg,pertuzumab)have significantlyextended life, perhapsgiv-
ing reason for large and growing expenditures. Others, how-
ever, appear tobring little tono tangible benefit tohealth, rais-
ingquestionsabout the justificationforadditionalexpenseover
alternative treatments.Though further research isneeded,our
analysismay indicate that spendingonnewcancerdrugs isnot
always commensuratewith their clinical benefits. Thismaybe
reason for patients and clinicians to take pause when consid-
ering new treatments, particularly if related expenditures are
of concern.
Conclusions
Cancer drug innovationover thepast decade is, on thewhole,
expected to have contributed to improvements in patient OS
andQoL.Thesegains,however,areunevenlydistributedacross
all newly licensedmedicines, often come at the cost of safety,
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and may not always translate to real-world practice. As calls
for value-based health care grow, this analysis raises ques-
tions about how clinical benefits aremeasured by regulators,
how regulatory guidance is used to inform clinical decision-
making, and how much value is generated from spending in
the oncology drug market.
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eExhibits 
eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003-2013 (Summary of eTable 2) 
 
Active ingredient FDA- or EMA-approved indication 
Appraisal 
dates 
 
Comparator(s) OS effect
a (in 
months) 
 
QoL effect 
 
Safety effect 
Ascites 
catumaxomab Ascites (EMA) Dec 09 paracentesis NE NE NE 
Bladder 
 
vinflunine Carcinoma of the urothelial tract (EMA) 
 
Dec 09–Jan 13 
 
BSC 
Exact 
magnitude 
uncertain 
 
NE 
 
Reduction 
Breast 
ado-trastuzumab 
emtansine Breast cancer Mar 14–Nov 14 lapatinib + capecitabine ≥ 3 (5.8) Improvement 
Mixed 
evidence 
eribulin Breast cancer Jul 11–Nov 13 TPC < 3 (2.5–2.7) NE Reduction 
ixabepilone Breast cancer n/a n/a n/a n/a n/a 
lapatinib Breast cancer Nov 07–May 10 capecitabine  monotherapy < 3 (0.3–2.4) NE Reduction 
pertuzumab Breast cancer Jul 13–Mar 14 trastuzumab + docetaxel ≥ 3 (15.7) Improvement Reduction 
Gastro-intestinal 
bevacizumab Colorectal carcinoma Jun 05–Jul 08 IFL/5-FU/LV ≥ 3 (3.0–4.7) NE Reduction 
 
cetuximab 
 
Colorectal carcinoma 
 
Mar 05–Mar 09 
 
BSC 
Exact 
magnitude 
uncertain 
 
NE 
 
Reduction 
panitumumab Colorectal carcinoma Apr 08–Nov 13 BSC/cetuximab  (safety) ≥ 3 (2.7–3.2) NE NE 
regorafenib Colorectal cancer May 14–Jul 14 placebo < 3 (1.4) NE Reduction 
tegafur/gimeracil/oteracil Gastric cancer (EMA) Oct 12–Mar 13 5-FU/cisplatin NE NE NE 
ziv-aflibercept Colorectal cancer Jul 13–Mar 14 placebo < 3 (1.4) Improvement Reduction 
Gastro-intestinal/Renal 
sunitinib Gastrointestinal stromal tumor / Renal cell carcinoma 
Sep 06–Sep 09 / 
May 07–Mar 09 BSC/interferon-alfa 
≥ 3 (7.8) / ≥ 3 
(10.0) Improvement Reduction 
Hematological 
asparaginase E. 
chrysanthemi Acute lymphoblastic leukemia n/a n/a n/a n/a n/a 
azacitidine Myelodysplastic  syndromes Jul 09–Mar 11 conventional care ≥ 3 (9.4–9.6) Improvement Reduction 
bendamustine Lymphocytic  leukemia Oct 10–Feb 11 chlorambucil NE Reduction Reduction 
bortezomib Multiple myeloma Oct 04–Oct 07 high-dose  dexamethasone ≥ 3 (6.1–11.5) Improvement Mixed evidence 
bosutinib Chronic myelogenous leukemia Nov 13–Feb 14 BSC ≥ 3 (exact gain uncertain) NE Improvement 
brentuximab vedotin Hodgkin lymphoma / Systemic Mar 13–Mar 14 multi-agent salvage Exact NE Mixed 
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 lymphoma  chemotherapy magnitude 
uncertain 
 evidence 
carfilzomib Multiple myeloma n/a n/a n/a n/a n/a 
clofarabine Acute lymphoblastic leukemia Dec 06 non-comparative NE NE NE 
dasatinib Chronic myeloid leukemia // Acute lymphoblastic  leukemia Mar 07–Jan 12 non-comparative NE NE 
Mixed 
evidence 
decitabine Myelodysplastic  syndromes n/a n/a n/a n/a n/a 
ibrutinib Mantle cell lymphoma n/a n/a n/a n/a n/a 
 
lenalidomide Transfusion-dependent anemia due to myelodysplastic  syndromes 
 
Mar 13–Nov 14 
 
placebo 
Exact 
magnitude 
uncertain 
 
Improvement 
 
Reduction 
nelarabine Acute lymphoblastic leukemia / Lymphoblastic  lymphoma Dec 07 non-comparative NE NE NE 
nilotinib Chronic myelogenous leukemia Feb 08–Jan 12 non-comparative NE NE Improvement 
 
obinutuzumab 
 
Chronic lymphocytic leukemia 
 
Jul 14–Mar 15 
 
chlorambucil 
Exact 
magnitude 
uncertain 
 
Mixed evidence Mixed evidence 
ofatumumab Chronic lymphocytic leukemia Oct 10–Nov 14 chlorambucil NE NE NE 
omacetaxine 
mepesuccinate Chronic myeloid leukemia n/a n/a n/a n/a n/a 
pomalidomide Multiple myeloma Jan 14–Mar 15 standard care / high-dose dexamethasone (safety) 
≥ 3 (exact gain 
uncertain) Improvement Reduction 
ponatinib Chronic myeloid leukemia / Acute lymphoblastic  leukemia Nov 14–Jan 15 dasatinib/nilotinib NE NE Reduction 
pralatrexate Peripheral lymphoma n/a n/a n/a n/a n/a 
romidepsin Cutaneous lymphoma n/a n/a n/a n/a n/a 
 
ruxolitinib 
 
Myelofibrosis 
 
Jan 13–Jul 13 
 
BSC 
Exact 
magnitude 
uncertain 
 
Improvement 
 
Reduction 
tositumomab Non-Hodgkin’s  lymphoma n/a n/a n/a n/a n/a 
vorinostat Cutaneous lymphoma Mar 11 BSC NE NE Mixed evidence 
Lung 
afatinib Non-small cell lung cancer Jul 13–Apr 14 erlotinib/gefitinib NE Improvement Reduction 
crizotinib Non-small cell lung cancer Sep 13–Nov 14 pemetrexed ≥ 3 (3.1–3.5) Improvement NE 
erlotinib Non-small cell lung cancer Mar 06–Nov 08 placebo/BSC < 3 (2.0) Improvement Mixed evidence 
gefitinib Non-small cell lung cancer Nov 09–Jul 13 paclitaxel + carboplatin NE Improvement Improvement 
pemetrexed Pleural  mesothelioma Mar 05–Jan 08 cisplatin ≥ 3 (2.8–3.3) Improvement Reduction 
Prostate 
abiraterone acetate Prostate cancer Feb 12–Jul 12 BSC (prednisolone) ≥ 3 (3.9–4.6) Improvement Improvement 
cabazitaxel Prostate cancer Nov 11–Oct 12 mitoxantrone ≥ 3 (2.4–4.2) NE Reduction 
degarelix Prostate cancer Sep 09–Apr 14 leuproprelin + LHRH agonists NE NE Reduction 
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enzalutamide Prostate cancer Nov 13–Jul 14 placebo ≥ 3 (4.5–4.8) Improvement Mixed evidence 
radium-223 dichloride Prostate cancer Apr 14 placebo < 3 (2.8) NE NE 
sipuleucel-T Prostate cancer Feb 15 BSC ≥ 3 (4.0) Improvement Improvement 
Renal 
axitinib Renal cell carcinoma Jan 13–Feb 15 BSC ≥ 3 (exact gain uncertain) NE 
Mixed 
evidence 
everolimus Renal cell carcinoma Nov 09–Apr 11 BSC ≥ 3 (5.2) Improvement Reduction 
pazopanib Advanced renal cell carcinoma Feb 11–Jun 13 BSC/interferon-alfa ≥ 3 (exact gain uncertain) NE 
Mixed 
evidence 
sorafenib Renal cell carcinoma Sep 06–Aug 09 BSC ≥ 3 (exact gain uncertain) Improvement Reduction 
temsirolimus Renal cell carcinoma Feb 08–Aug 09 interferon-alfa ≥ 3 (3.6) Improvement Improvement 
Skin 
 
dabrafenib 
 
Melanoma 
 
Oct 14 dacarbazine/vemurafenib (safety) 
Exact 
magnitude 
uncertain 
 
Reduction 
 
Improvement 
ipilimumab Melanoma Nov 12–Nov 14 dacarbazine ≥ 3 (5.7) NE Reduction 
 
trametinib 
 
Melanoma 
 
Nov-14 
 
dabrafenib 
Exact 
magnitude 
uncertain 
 
Improvement 
 
NE 
vemurafenib Melanoma Oct 12–Mar 13 dacarbazine ≥ 3 (3.3–3.9) Improvement Reduction 
vismodegib Basal cell carcinoma Dec 13 non-comparative NE NE NE 
Soft tissue 
trabectedin Soft tissue sarcoma (EMA) Apr 08–Feb 10 BSC ≥ 3 (exact gain uncertain) NE Improvement 
Thyroid 
cabozantinib Medullary thyroid cancer Dec14 placebo NE NE Reduction 
vandetanib Medullary thyroid cancer Jun 12 placebo NE NE NE 
 
 
Source: Authors’ analysis of data from sources identified in the “Methods” section. 
 
Notes: 
Drug and therapeutic features associated with all new cancer medicines approved by the FDA between 2003-2013, and appraised by NICE, HAS, or PBAC through May 2015. Change in overall survival 
(OS), quality of life (QoL) and safety is given as composite magnitude of therapeutic improvement for each drug relative to existing standards of care across all three HTA agencies (see Methods). 
 
n/a = no appraisal available through May 2015. 
NE = none established. 
a OS benefits are classified as a categorical variable (months). A range (in parentheses) was also developed to reflect the maximum OS benefit acknowledged by the HTA agencies that were able to 
quantify the magnitude of gain. 
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eTable 2. Regulatory evidence in support of classification of drug clinical benefits 
 
abiraterone acetate FDA primary indication 
ATC code: L02BX03  
A CYP17 inhibitor indicated for use in combination with prednisone for the treatment of patients with metastatic castration- 
resistant prostate cancer who have received prior chemotherapy containing docetaxel. Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency NICE HAS PBAC 
Appraisal date Jun-12 Feb-12 Jul-12 
Comparator BSC (prednisolone) BSC (prednisolone) BSC (prednisolone) 
Modelled/indirect  comparison No No No 
Basis for classification OS: 4.6-month increase in median OS 
compared to prednisolone; estimated 
mean overall survival gain was greater 
than 3 months, though exact value was 
"commercial in confidence" 
 
QoL: Committee concluded that 
abiraterone offers a step change in 
treatment because it is an oral drug 
taken by patients at home, and is 
associated with few adverse reactions. 
The benefit related to being an oral drug 
was not captured in the analysis 
because the model applied the same 
utility benefit to abiraterone as to 
mitoxantrone. Committee therefore 
acknowledged that abiraterone provides 
HRQoL benefits other than those 
captured in the QALY calculation for 
patients currently receiving 
mitoxantrone 
Safety: The Committee also noted that 
abiraterone is not associated with the 
more severe adverse reactions that can 
OS: 3.9-month increase in median OS 
compared to placebo (prednisone or 
prednisolone) 
 
QoL: The patients’ quality of life 
deteriorates less under treatment than 
with placebo 
 
Safety: No judgment given on 
comparative differences in safety 
OS: 3.9-month increase in median OS 
compared to BSC (prednisone/ 
prednisolone plus other care); OS 
increase compared to mitoxantrone 
(based on indirect comparison), though 
magnitude of increase not given; no 
significant increase compared to 
cabazitaxel (based on indirect 
comparison) 
 
QoL: Statistically significant differences 
in functional assessment of cancer 
therapy – prostate (FACT-P) scores 
between the abiraterone and placebo 
arms of Trial 301 were demonstrated. 
However, the magnitude of changes in 
FACT-P Total Scores between trial arms 
were small and changes in subscale 
FACT-P scores were similar in both 
groups 
 
Safety: Whilst PBAC considered there 
were uncertainties inherent from indirect 
comparisons, it accepted the 
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 occur with cytotoxic drugs such as 
mitoxantrone. The Committee heard 
from the clinical specialists that 
abiraterone is a well-tolerated oral 
medication 
 submission’s clinical claims: 
(1) abiraterone + prednisone/ 
prednisolone is equivalent in terms of 
comparative safety over BSC 
(prednisone/prednisolone  alone); 
(2) abiraterone + prednisone/ 
prednisolone is superior in terms of 
comparative safety over mitozantrone 
plus prednisone/prednisolone alone; 
(3) abiraterone + prednisone/ 
prednisolone is superior in terms of 
comparative safety over cabazitaxel 
plus prednisone/prednisolone alone 
Effects Merged data    
OS increase 3.9–4.6 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + + + 
Safety change + + NA No difference (BSC); + (mitoxantrone); + (cabazitaxel) = + 
 
ado-trastuzumab emtansine FDA primary indication 
ATC code: L01XC14 HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with 
HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. 
Patients should have either: 
(a) Received prior therapy for metastatic disease, or 
(b) Developed disease recurrence during or within six months of completing adjuvant therapy. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Breast 
Agency NICE HAS PBAC 
Appraisal date Aug-14 Mar-14 Nov-14 
Comparator lapatinib + capecitabine lapatinib + capecitabine lapatinib + capecitabine 
Modelled/indirect  comparison No No No 
Basis for classification OS: 5.8-month increase in median OS 
compared to lapatinib + capecitabine 
QoL: The Committee was aware that 
EMILIA was an open- label trial, which 
may have introduced bias in the 
OS: 5.8-month increase in median OS 
compared to lapatinib + capecitabine 
QoL: In view of the available results 
from clinical trials, especially the 
EMILIA study, ado-trastuzumab is 
OS: 5.8-month increase in median OS 
compared to lapatinib + capecitabine 
QoL: The PBAC noted strong support 
for the listing of T-DM1 received through 
the consumer comments facility 
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 outcomes reported by patients, but 
concluded that a marginally higher 
utility value for trastuzumab emtansine 
in the progression-free state could be 
accepted in this appraisal 
 
Safety: The Committee understood that 
fewer patients stopped treatment 
because of an adverse event in the 
trastuzumab emtansine group than in 
the lapatinib + capecitabine group 
expected to have a moderate impact in 
terms of morbidity, mortality and QoL 
 
Safety: A smaller proportion of AEs of 
grade 3 or worse and serious AEs 
(SAE) of grade 3 or worse was 
reported in the trastuzumab emtansine 
group compared to the control group 
expressing a range of benefits from 
treatment including improved QoL 
 
Safety: T-DM1 second-line: the 
previous resubmission described T-DM1 
as superior in terms of comparative 
safety over lapatinib plus capecitabine. 
In March 2014, the PBAC accepted this 
clinical claim, although noted that some 
of the toxicity profile of T-DM1 was less 
favourable than that of its comparator 
Effects Merged data    
OS increase 5.8 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + + + 
Safety change +/- + + +/- 
 
afatinib FDA primary indication 
ATC code: L01XE13  
A kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose 
tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as 
detected by an FDA-approved test. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Lung 
Agency NICE HAS PBAC 
Appraisal date Apr-14 Feb-14 Jul-13 
Comparator erlotinib, gefitinib cisplatin-based chemotherapy erlotinib, gefitinib 
Modelled/indirect  comparison No No No 
Basis for classification OS: Committee concluded that on 
balance afatinib is likely to have similar 
clinical efficacy to erlotinib and gefitinib. 
Because of the immaturity of the OS 
data available, there was uncertainty 
about whether treatment with afatinib 
resulted in OS benefit compared with 
chemotherapy, therefore no increase 
OS: In view of the available clinical 
data and in comparison with cisplatin- 
based chemotherapy, it should be 
noted that there is no improvement in 
terms of OS 
QoL: In view of the available clinical 
data and in comparison with cisplatin- 
based chemotherapy, a moderate 
OS: PBAC noted that there was no 
significant survival advantage reported 
for afatinib or the other two TKIs in trials 
considered. Comparing afatinib with 
chemotherapy, there was no observed 
benefit in OS 
 
QoL: PBAC considered that the benefit 
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 was established 
 
QoL: The Committee did not draw any 
specific conclusions about the HRQoL 
benefits and utility values 
 
Safety: The Committee concluded that 
although afatinib has a different 
adverse reaction profile from erlotinib 
and gefitinib, overall the toxicity of the 
tyrosine kinase inhibitors was similar 
additional impact QoL is expected in 
patients treated with first-line afatinib. 
In the absence of any clinical data 
comparing afatinib with other tyrosine 
kinase inhibitors, the medicinal product 
afatinib is not expected to have any 
additional impact on QoL in the current 
treatment strategy for these patients 
 
Safety: While HAS makes a few claims 
on AE rates, the agency gives no 
assessment of comparative differences 
in safety 
of afatinib was due only to a 
prolongation of PFS which is associated 
with some improvement in QoL 
 
Safety: PBAC considered that many 
serious adverse events including grade 
3 or higher appeared more often in the 
afatinib arm compared to the 
cisplatin/pemetrexed arm. They noted 
that there were relatively high rates of 
adverse events (AEs) associated with 
afatinib relative to doublet platinum 
chemotherapy, including more Grade 3 
or higher AEs, in the LUX Lung 3 trial. 
There was a higher proportion of dose 
reductions during treatment with afatinib 
compared to treatment with either 
gefitinib or erlotinib, although there were 
limitations for those indirect comparison 
Effects Merged data    
OS increase None established None established None established None established 
QoL change + NA + (cisplatin); No difference (TKIs) = + + 
Safety change - No difference NA - 
 
asparaginase E. 
chrysanthemi FDA primary indication 
ATC code: L01XX02  
An asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of 
patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. Orphan Status: EU 
Licensure: FDA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
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Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
axitinib FDA primary indication 
ATC code: L01XE17  
 
A kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. Orphan Status: EU (w) 
Licensure: FDA/EMA 
Target: Renal 
Agency NICE HAS PBAC 
Appraisal date Feb-15 Jan-13 Nov-14 
Comparator BSC sorafenib everolimus 
Modelled/indirect  comparison Yes No Yes 
Basis for classification OS: More than 3-month increase 
compared to BSC was "likely" (based 
on indirect and simulated treatment 
comparisons), though exact magnitude 
of increase was uncertain as the 
comparison results were "improbable"; 
Committee concluded that axitinib "was 
likely to have clinical effectiveness 
comparable to pazopanib and sunitinib" 
 
QoL: NICE was satisfied with the 
HRQoL data collected and found no 
significant difference versus sorafenib 
in FKSI-15. QoL was maintined while 
patients remained in both treatment 
groups. For EQ-5D, the overall 
between-treatment comparison for 
axitinib compared with sorafenib was 
OS: An increase compared to sorafenib 
was not established in the overall 
population or patient subgroups as no 
statistically significant difference was 
observed; Committee considered that 
the indirect comparison to everolius 
was "exploratory in nature from [which] 
no conclusions can be drawn with a 
sufficient level of evidence" 
 
QoL: In view of the clinical study 
results showing no gain in terms of 
overall survival or quality of life, the 
expected impact of axitinib in terms of 
morbidity, mortality and quality of life 
can only be small 
Safety: The frequency of serious 
adverse events was of the same order 
OS: An increase compared to 
everolimus was not established given 
"the limitations of the comparative 
evidence and the methodological 
limitations of the simulated treatment 
comparison and matching-adjusted 
indirect comparison", though Committee 
accepted claim of non-inferiority 
 
QoL: NA 
 
Safety: PBAC accepted the clinical 
claim that axitinib is non-inferior to 
everolimus in terms of comparative 
effectiveness and safety 
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 not statistically significant (no p value 
given); however, QoL was maintained 
while patients remained on treatment 
and declined when patients stopped 
trial medication 
 
Safety: The Committee noted that 
diarrhoea occurred with similar 
frequency in the axitinib and sorafenib 
groups. It was aware that hypertension, 
dysphonia, nausea and hypothyroidism 
occurred more frequently in the axitinib 
group, although hand–foot syndrome, 
rash and alopecia occurred more 
frequently in the sorafenib group. The 
Committee concluded that axitinib has a 
manageable adverse event profile 
compared with other treatments 
between axitinib and sorafenib  
Effects Merged data    
 
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 
 
None established 
 
None established 
QoL change None established No difference No difference NA 
Safety change +/- +/- No difference No difference 
 
azacitidine FDA primary indication 
ATC code:   L01BC07  
Indicated for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory 
anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory 
anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Mar-11 Apr-09 Jul-09 
Comparator conventional care conventional care conventional care 
Modelled/indirect  comparison No No No 
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Basis for classification OS: 9.6-month increase in median OS 
compared to conventional care 
regimens (i.e. BSC, low-dose 
chemotherapy, and standard-dose 
chemotherapy); OS increase significant 
compared to BSC and low-dose 
chemotherapy, but not significant 
compared to standard-dose 
chemotherapy though the Committee 
"was aware that the small patient 
numbers limited the precision and 
certainty of the outcome estimates in 
these groups" 
 
QoL: Committee heard from the patient 
experts that compared with other 
treatment options, azacitidine was 
associated with relief from fatigue, 
fewer infection-related hospitalisations, 
a decreased need for blood and platelet 
transfusion, and increased ability to 
perform day-to-day activities. No QoL 
data were collected in AZA-001, 
although EORTC data collected in 
CALGB 9221 suggested improvements 
in overall health with azacitidine. 
 
Safety: No comparative assessment 
made on AEs and safety 
OS: 9.4-month increase in median OS 
compared to conventional care 
regimens (i.e. no active treatment, low- 
dose cytarabine, and standard 
chemotherapy) 
 
QoL: In view of the available clinical 
data and current therapeutic strategies, 
azacitidine is expected to have a 
significant impact on morbidity, 
mortality and QoL 
 
Safety: No explicit judgment provided 
discussing the comparative evidence 
on drug-related changes in AEs and 
safety 
OS: 9.4-month increase in median OS 
compared to conventional care 
regimens (i.e. BSC, low-dose 
cytarabine, and standard-dose 
chemotherapy) in patients with high risk 
MDS 
 
QoL: No explicit discussion on HRQoL 
data, though there is a brief discussion 
of the "paucity of available utility data" 
and the "uncertainty" in the values used 
in submitted health economic 
evaluations 
 
Safety: PBAC agreed that BSC (which 
included low dose cytarabine and 
standard chemotherapy) was the 
appropriate comparator and that the 
clinical trial data supported the claim 
that azacitidine was significantly more 
effective than conventional care but was 
associated with more toxicity when used 
for the treatment of INT-2/high risk MDS 
patients 
Effects Merged data    
OS increase 9.4–9.6 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + + NA 
Safety change - NA NA - 
 
bendamustine FDA primary indication 
ATC code: L01AA09 An alkylating drug indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line 
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Orphan Status: US therapies other than chlorambucil has not been established. 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Feb-11 Oct-10 NA 
Comparator chlorambucil chlorambucil NA 
Modelled/indirect  comparison No No NA 
emBasis for classification OS: No statistically significant 
difference in median OS between 
bendamustine and chlorambucil 
 
QoL: During the treatment period, 
patients' QoL was assessed using the 
EORTC questionnaires. Patients' 
overall QoL was modestly improved in 
both groups during treatment, with no 
significant differences between the 
groups. The manufacturer explained in 
its submission that the QOL data 
collected during the trial showed that 
patients receiving the more effective 
therapy (bendamustine) experienced a 
greater number of adverse events 
during the treatment period, leading to a 
QoL detriment in some health 
dimensions 
 
Safety: The only available treatment for 
these patients is chlorambucil. The 
Committee heard that although 
bendamustine is slightly more toxic and 
is associated with more AEs, the clinical 
specialists considered bendamustine to 
be the more effective treatment. The 
Committee also noted the views of the 
patient groups in their submissions to 
NICE that because of its improved 
efficacy compared with chlorambucil, 
OS: Insignificant difference in terms of 
median OS compared to the 
benchmark (65.4 months in the 
chlorambucil group and not achieved in 
the bendamustine group) 
 
QoL: There is a lack of HRQoL data 
 
Safety: HAS noted that grade 3–4 
adverse events were more common in 
the bendamustine group than in the 
chlorambucil group, especially 
haematological adverse events and 
infections 
NA 
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 people with the condition would be 
willing to accept the side effects 
  
Effects Merged data    
OS increase None established None established None established NA 
QoL change - - NA NA 
Safety change - - - NA 
 
bevacizumab FDA primary indication 
ATC code: L01XC07  
In combination with intravenous 5-fluorouracil–based chemotherapy is indicated for first- line treatment of patients with 
metastatic carcinoma of the colon or rectum. Orphan Status: – 
Licensure: FDA/EMA 
Target: GI 
Agency NICE HAS PBAC 
Appraisal date Jan-07 Jun-05 Jul-08 
Comparator IFL IFL IFL or 5-FU/LV 
Modelled/indirect  comparison No No No 
Basis for classification OS: 4.7-month increase in median OS 
compared to IFL (irinotecan, bolus 5-FU 
and leucovorin); no significant 
difference compared to 5-FU/LV (two 
studies); Committee noted that the 
comparators "cannot be considered 
current standard practice in NHS," 
though was "persuaded that the results 
seen in the studies could be considered 
generalizable to NHS practice" 
 
QoL: Committee recommends studies 
to investigate the impact of 
bevacizumab and cetuximab treatment 
on HRQoL 
 
Safety: In all the studies there was a 
OS: 4.7-month increase in median OS 
compared to IFL (first-line); no 
significant difference in median OS was 
observed compared to FUFOL (5-FU 
plus folinic acid) 
 
QoL: Time to deterioration in QoL were 
similar in both groups 
 
Safety: In the pivotal study, grade 3-4 
toxicity was higher in the IFL + Avastin 
group than in the IFL alone group 
OS: 3- to 4-month increase in OS 
compared to first-line chemotherapy (i.e. 
IFL or 5-FU/LV), although the 
differences were not statistically 
significant in two of the three trials; 
Committee also noted that IFL was "no 
longer accepted as best practice in 
Australia or the USA" 
 
QoL: No HRQoL data presented 
 
Safety: Overall, the risk of several AEs, 
particularly hypertension, proteinuria and 
arterial thromboembolic events, was 
found to be elevated following the 
addition of bevacizumab to 
chemotherapy 
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 higher incidence of grade 3 and 4 
adverse events in the groups receiving 
bevacizumab compared with the control 
groups 
  
Effects Merged data    
OS increase 3.0–4.7 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change None established NA No Difference NA 
Safety change - - - - 
 
bortezomib FDA primary indication 
ATC code: L01XX32 bortezomib for injection is indicated for the treatment of multiple myeloma patients who have received at least two prior 
therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on 
response rates (see CLINICAL STUDIES section). There are no controlled trials demonstrating a clinical benefit, such as an 
improvement in survival. 
Orphan Status: US 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Oct-07 Oct-04 Mar-06 
Comparator high-dose dexamethasone Not given high-dose dexamethasone 
Modelled/indirect  comparison No Yes No 
Basis for classification OS: 6.1-month increase in median OS 
compared to high-dose dexamethasone 
 
QoL: No HRQoL information provided. 
Further research into the effectiveness 
of bortezomib for the treatment of 
relapsed multiple myeloma is needed. 
Such studies should include: 
measurement of quality of life in 
patients with relapsed multiple 
myeloma, including the effect of 
treatment and adverse events 
 
Safety: Committee understood from the 
OS: 8.5- to 11.5-month improvement in 
median survival based on comparison 
of OS data from single-arm bortezomib 
study and OS data from literature for 
similar patient population 
 
QoL: Regarding QoL treatment, 
improved items including the overall 
score of QoL, the physical score and 
social score were observed in 2 of the 
three scales used (QLQ-C30 scale 
EORTC-QLQ Module MY24). Variation 
of the scores of the FACIT-Fatigue 
scale score was not statistically 
OS: Committee "acknowledged that 
bortezomib has significant advantages  
in the short term over the comparator 
HDD in terms of…increasing the 
proportion of individuals alive at one 
year" but noted that "a number of 
uncertainties arose over the 
interpretation of the...trial results," 
including wide 95% confidence intervals, 
significant patient crossover, and 
"doubts about the acceptability of HDD 
as being representative for the main 
comparator" 
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 clinical specialists that there was a 
greater frequency of peripheral 
neuropathy and gastrointestinal adverse 
effects in the bortezomib arm, but     
that bortezomib was associated with 
less bone destruction and fewer 
infections than HDD 
significant 
 
Safety: No comparative data 
QoL: NA 
 
Safety: Overall incidence of AEs were 
similar in both groups, with 100% of 
bortezomib patients and 98% of HDD 
patients experiencing one AE. Overall 
pattern of AE differed. Incidence of 
Grade 3 and those leading to 
discontinuation was higher in the 
bortezomib group 
Effects Merged data    
OS increase 6.1–11.5 months ≥ 3 months ≥ 3 months Uncertain 
QoL change + NA + NA 
Safety change +/- +/- NA - 
 
bosutinib FDA primary indication 
ATC code: L01XE14  
 
A kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic 
myelogenous leukemia (CML) with resistance or intolerance to prior therapy. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Nov-13 Feb-14 NA 
Comparator BSC NA NA 
Modelled/indirect  comparison Yes No NA 
Basis for classification OS: At least 3-month extension 
compared to BSC, though exact 
magnitude of increase uncertain (based 
on modeled data) 
 
QoL: NA 
 
Safety: The Committee heard from a 
patient expert that, in their own 
OS: An increase was not established 
given the lack of comparative data 
presented to the Committee 
 
QoL: The proprietary medicinal product 
bosutinib is not expected to have any 
impact on morbidity, mortality or QoL in 
comparison with cited treatments 
NA 
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 experience, previous tyrosine kinase 
inhibitors had resulted in them being 
unable to work and needing cardiac and 
surgical interventions. However, 
bosutinib had been tolerated 
Safety: No comparative data available  
Effects Merged data    
 
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 
 
None established 
 
NA 
QoL change None established NA No difference NA 
Safety change + + NA NA 
 
brentuximab vedotin FDA primary indication 
ATC code: L01XC12  
A CD30-directed antibody-drug conjugate indicated for: (a) Hodgkin lymphoma after failure of autologous stem cell transplant 
(ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates; and 
(b) Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen. These 
indications are based on response rate. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA Mar-13 Mar-14 
Comparator NA non-comparative multi-agent salvage chemotherapy 
Modelled/indirect  comparison NA No No 
Basis for classification NA OS: Median OS was not achieved 
during the primary analysis and does 
not enable conclusions to be drawn 
regarding this endpoint; available data 
are not sufficient (absence of 
comparative data in particular) to 
enable an evaluation of the expected 
impact of brentuximab vedotin on the 
morbidity, mortality and quality of life of 
patients treated 
OS: The PBAC accepted the claim that 
BV is associated with significant 
additional OS and patient relevant 
efficacy in the first line salvage setting 
for patients that have had no prior SCT 
 
QoL: NA 
Safety: PBAC considered that the 
submission’s claim of less toxicity 
relative to multi-agent salvage 
chemotherapy was reasonable with 
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  QoL: NA 
 
Safety: No comparative data available 
respect to most acute toxicity, but that 
severe peripheral neuropathy was an 
important toxicity more likely in BV 
treated patients 
Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
NA 
 
None established 
 
Uncertain 
QoL change None established NA NA NA 
Safety change +/- NA NA +/- 
 
cabazitaxel FDA primary indication 
ATC code: L01CD04  
A microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic 
prostate cancer previously treated with a docetaxel-containing treatment regimen. Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency NICE HAS PBAC 
Appraisal date May-12 Oct-12 Nov-11 
Comparator mitoxantrone mitoxantrone mitoxantrone 
Modelled/indirect  comparison Yes No No 
Basis for classification OS: More than 3-month increase 
compared to mitoxantrone (4.2 months 
based on modeled mean OS gain); 2.4- 
month increase in median OS was 
observed in the trial 
 
QoL: No statistically significant 
difference in pain response between the 
treatment arms. No significant 
difference in time to pain progression 
between the treatment arms 
 
Safety: The Committee was initially 
OS: 4.1-month increase in median OS 
compared to mitoxantrone in subgroup 
of patients who had stopped treatment 
due to disease progression and had a 
histologically poorly differentiated 
tumor; 2.4-month increase in median 
OS compared to mitoxantrone in the 
whole trial population 
 
QoL: In the absence of data, the 
impact on the QoL of treated patients is 
not quantifiable. Nevertheless, a 
negative impact (safety issues) on QoL 
OS: 2.4-month increase in median OS 
compared to mitoxantrone; Committee 
stated that the modeled mean OS gain 
of 4.26 months appeared to be an 
overestimate and was uncertain 
 
QoL: A regulatory judgment of the 
submitted HRQoL (Q-TWIST) evidence 
is not given 
Safety: The PBAC agreed that the 
clinical claim that cabazitaxel is superior 
in terms of comparative effectiveness 
and inferior in terms of comparative 
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 concerned that in TROPIC more 
participants in the cabazitaxel arm died 
from cardiac and renal complications 
than in the mitoxantrone arm. The 
Committee concluded that there is no 
evidence of additional risk other than 
that included in the SPC and that the 
health economic model adequately 
reflected the disutility associated with 
adverse reactions. The Committee 
further heard that patient experts are 
aware that cabazitaxel is associated 
with serious ARs and that it would not 
be suitable for some patients who are 
not fit for chemotherapy 
cannot be ruled out 
 
Safety: Safety was not as good in the 
cabazitaxel group as in the 
mitoxantrone group 
safety over mitozantrone is reasonable 
Effects Merged data    
OS increase 2.4–4.2 months ≥ 3 months ≥ 3 months < 3 months 
QoL change None established No difference NA NA 
Safety change - - - - 
 
cabozantinib FDA primary indication 
ATC code: L01XE26  
A kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). 
Orphan Status: US 
Licensure: FDA/EMA 
Target: Thyroid 
Agency NICE HAS PBAC 
Appraisal date NA Dec-14 NA 
Comparator NA placebo NA 
Modelled/indirect  comparison NA No NA 
Basis for classification NA OS: The available data showed no 
benefit, and given current therapeutic 
strategies, low impact in terms of 
NA 
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  morbidity and mortality is expected 
 
QoL: The available clinical data 
(including a Phase III placebo- 
controlled trial) showed a gain of 7 
months progression-free survival with 
better response rates, but no benefit on 
overall survival or profit (or worsening) 
of QoL 
 
Safety: Treatment discontinuations due 
to adverse events were higher for 
patients in the cabozantinib group 
versus placebo patients 
 
Effects Merged data    
OS increase None established NA None established NA 
QoL change None established NA No difference NA 
Safety change - NA - NA 
 
carfilzomib FDA primary indication 
ATC code: L01XX45  
A proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior 
therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 
days of completion of the last therapy. Approval is based on response rate. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
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QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
catumaxomab FDA primary indication 
ATC code: L01XC09  
indicated for the intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard 
therapy is not available or no longer feasible. Orphan Status: US/EU 
Licensure: EMA 
Target: Ascites 
Agency NICE HAS PBAC 
Appraisal date NA Dec-09 NA 
Comparator NA paracentesis NA 
Modelled/indirect  comparison NA No NA 
Basis for classification NA OS: Median OS did not differ between 
the two groups: 72 days in the 
REMOVAB group compared with 68 
days in the control group 
 
QoL: In view of the methodology of the 
study (open-label), QoL data are 
difficult to interpret. The need for 11 
days of hospitalisation for the treatment 
while no evidence is available of an 
improvement in QoL 
 
Safety: No comparative evidence 
presented 
NA 
Effects Merged data    
OS increase None established NA None established NA 
QoL change None established NA No difference NA 
Safety change None established NA NA NA 
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cetuximab FDA primary indication 
ATC code: L01XC06  
Used in combination with irinotecan for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who 
are refractory to irinotecan-based chemotherapy. cetuximab administered as a single agent is indicated for the treatment of 
EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: GI 
Agency NICE HAS PBAC 
Appraisal date Jan-07 Mar-05 Mar-09 
Comparator cetuximab monotherapy cetuximab monotherapy BSC 
Modelled/indirect  comparison No No Yes 
Basis for classification OS: No statistically significant 
difference in median OS between 
cetuximab-irinotecan  combination 
therapy and cetuximab monotherapy. 
Relative effectiveness against current 
standard care remains uncertain 
 
QoL: The Committee recommends 
studies to investigate the impact of 
bevacizumab and cetuximab treatment 
on health-related quality of life 
 
Safety: In the RCT the incidence of 
some AEs was higher in patients 
receiving cetuximab plus irinotecan 
compared with those receiving 
cetuximab alone: grade 3 and 4 
adverse events; diarrhoea; neutropenia; 
grade 3 or 4 acne-like rash. 
OS: No gain in OS has been 
demonstrated between cetuximab- 
irinotecan and cetuximab monotherapy 
 
QoL: Available data do not allow to 
quantify the contribution of cetuximab 
in terms of quality of life vis-à-vis 
existing therapies 
 
Safety: 71% of patients in the 
combination group experienced at least 
one Grade 3–4 events against 53% 
monotherapy group 
OS: PBAC noted 3.6-month survival 
gain over BSC arm in modeled data. 
However, submission estimate likely 
overestimated the OS. PBAC 
considered that the extent of OS benefit 
over BSC in the KRAS subgroup 
remained uncertain 
 
QoL: For key results, see Nov 2008 
PSD. No information indicating drug- 
induced change 
 
Safety: For key results, see Nov 2008 
PSD. Cetuximab in combination with 
irinotecan tended to have more serious 
AEs and Grade 3/4 AEs compared to 
cetuximab monotherapy. These AEs 
were expected to be less in the BSC 
group. Cetuximab monotherapy had a 
greater incidence of any adverse event 
of grade 3 or higher compared to the 
BSC group (p<0.001). Patients in the 
cetuximab monotherapy group had a 
higher incidence of rash, infection 
without neutropenia, confusion and 
other pain as well as hypomagnesemia 
and infusion reactions 
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Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
None established 
 
None established 
 
Uncertain 
QoL change None established NA NA NA 
Safety change - - NA - 
 
clofarabine FDA primary indication 
ATC code: L01BB06  
Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two 
prior regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased 
survival or other clinical benefit have not been conducted. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA Dec-06 NA 
Comparator NA non-comparative NA 
Modelled/indirect  comparison NA Yes NA 
Basis for classification NA OS: Expected to have an impact in 
terms of morbi-mortality by facilitating 
access to an allograft. However, in the 
absence of a formalized comparison 
with historic data, the impact can only 
be small. Moreover, because of the 
uncertainty about drug tolerance, 
extrapolation of the test results to real 
life is itself uncertain. 
 
QoL: No comparative data presented 
to evaluate HRQoL 
 
Safety: Tolerance data are limited at 
present. No comparative evaluation of 
drug-related safety as comparator arm 
unavailable. Additional absence of 
"formalized comparisons with historical 
NA 
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  data on relapsed or refractory patients 
having had at least two previous 
treatments" 
 
Effects Merged data    
OS increase None established NA None established NA 
QoL change None established NA NA NA 
Safety change None established NA NA NA 
 
crizotinib FDA primary indication 
ATC code: L01XE16  
A kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer 
(NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. This indication is based 
on response rate. 
Orphan Status: - 
Licensure: FDA/EMA 
Target: Lung 
Agency NICE HAS PBAC 
Appraisal date Sep-13 Apr-13 Nov-14 
Comparator docetaxel pemetrexed or docetaxel pemetrexed 
Modelled/indirect  comparison Yes No Yes 
Basis for classification OS: Committee "accepted that 
treatment would result in  gain 
compared with docetaxel but the exact 
magnitude was uncertain; Committee 
"considered that the IPTCW2 method, 
which resulted in an OS benefit of 7.1 
months, may be a reasonable 
assumption given the lack of robust 
data" but that "an exact value could not 
be reliably established" 
QoL: Committee heard from the clinical 
specialists that patients with progressed 
disease continued to experience some 
additional health-related QoL benefit for 
OS: An increase compared to 
chemotherapy (i.e. docetaxel or 
pemetrexed) not established as no 
statistically significant difference was 
observed 
 
QoL: In view of the available clinical 
data, crizotinib showed a significant 
improvement in QoL versus docetaxel 
or pemetrexed 
Safety: No judgment given on 
comparative differences in drug-related 
safety profile 
OS: Committee considered the "likely 
incremental gain "is between 3.1 to 3.5 
months compared to pemetrexed 
(based on modeled data); Committee 
concluded that "given both the 
limitations of the randomized trial (small 
sample size, immature follow-up and 
post-progression cross-over to crizotinib 
in the pemetrexed arm) and also the 
usual concerns with attempting 
comparative treatment effect inferences 
by comparing across results for different 
groups of patients, no completely 
compelling conclusions could be drawn 
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 some time after treatment was 
withdrawn compared with those on 
chemotherapy, but that this would 
deteriorate over time. It accepted that 
some utility benefit might be expected 
from crizotinib discontinued at disease 
progression, though there are no data 
to suggest how great a benefit this 
might be or for how long it would 
persist. The Committee was also aware 
that there might be a benefit to utility of 
continuing crizotinib, but there were no 
data to show whether such continued 
treatment benefits patients or for how 
long 
 
Safety: The Committee concluded that 
crizotinib is associated with some ADRs 
but these would be tolerable for most 
patients and generally easily managed. 
 about the extent of incremental overall 
survival gain for crizotinib over 
pemetrexed" 
 
QoL: Consumer comments described a 
range of benefits, including the ability to 
return to work 
 
Safety: The PBAC accepted the claims 
for crizotinib having superior 
effectiveness and non-inferior safety 
compared to pemetrexed 
Effects Merged data    
OS increase 3.1–3.5 months Uncertain None established ≥ 3 months 
QoL change + + + + 
Safety change None established NA NA No difference 
 
dabrafenib FDA primary indication 
ATC code: L01XE23  
A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E 
mutation as detected by an FDA-approved test. Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency NICE HAS PBAC 
Appraisal date Oct-14 May-14 Mar-13 
Comparator dacarbazine dacarbazine DTIC 
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Modelled/indirect  comparison No No No 
Basis for classification OS: The Committee concluded that 
compared with dacarbazine, dabrafenib 
probably improved OS, but it was 
unable to draw firm conclusions about 
the magnitude of the benefit 
 
QoL: The mean change in EQ-5D utility 
index score from baseline to week 15 
was lower in the dabrafenib group than 
in the dacarbazine group 
 
Safety: The Committee concluded that 
the current evidence suggests that 
ADRs from dabrafenib treatment were 
not a major concern when compared 
with those from alternative treatments 
OS: In view of the available data, which 
shows no increase, the impact of 
dabrafenib on morbidity and mortality is 
considered low. On this date, there was 
no difference between the two 
therapeutic groups, dabrafenib vs 
dacarbazine (at six months) 
 
QoL: evaluatation using EORTC QLQ- 
C30 and EuroQoL EQ-5D 
questionnaires did not show any 
difference between the two treatment 
groups 
 
Safety: Treatment discontinuations due 
to adverse events were similar in both 
groups 
OS: Dabrafenib, unlike vemurafenib, 
has not demonstrated an unequivocal 
advantage over DTIC. There was no 
statistically significant difference both 
treatment groups. However, OS data at 
time of cut-off was not mature, therefore 
no conclusions could be drawn 
 
QoL: NA 
 
Safety: Dabrafenib and DTIC have 
different toxicity profiles, with dabrafenib 
being associated with manageable 
toxicity versus DTIC. PBAC noted that 
dabrafenib has a preferable toxicity 
profile vs vemurafenib as evidenced by 
fewer and less extensive dose intensity 
reductions and by favourable 
differences in rates for AEs such as 
photosensitivity, cutaneous squamous 
cell carcinoma – but not pyrexia 
Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
Uncertain 
 
None established 
 
None established 
QoL change - - No difference NA 
Safety change + No difference No difference NA (dacarbazine); + (vemurafenib) = + 
 
dasatinib FDA primary indication 
ATC code: L01XE06  
Indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia 
with resistance or intolerance to prior therapy including imatinib. 
Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with 
resistance or intolerance to prior therapy. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
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Appraisal date Jan-12 Mar-07 Jul-07 
Comparator non-comparative non-comparative non-comparative 
Modelled/indirect  comparison Yes Yes Yes 
Basis for classification OS: Clinical trials were non- 
comparative, of short duration and had 
used surrogate outcomes to predict OS. 
The Committee noted the poor quality 
of the evidence base 
 
QoL: No regulatory judgment made on 
comparative differences in HRQoL 
 
Safety: Committee concluded that 
dasatinib and nilotinib are better 
tolerated than imatinib, and that older 
treatments, particularly interferon alfa, 
can be poorly tolerated 
OS: Available clinical studies do not 
evaluate OS benefits directly 
 
QoL: No comparative data presented 
with which to evaluate comparative 
differences in HRQoL 
 
Safety: While safety of dasatinib 
evaluated, no comparison against other 
treatments is made 
OS: Clinical benefits as determined by 
number of patients achieving complete 
cytogenic response. Outstanding areas 
of concern for the Committee were 
whether cytogenetic response outcomes 
later in the course of the chronic phase 
of CML result in survival gain and, if so, 
what is the magnitude of the gain 
 
QoL: NA 
 
Safety: Evaluation indicated that 
dasatinib has significant advantages in 
effectiveness over imatinib but has more 
toxicity 
Effects Merged data    
OS increase None established None established None established None established 
QoL change None established NA NA NA 
Safety change +/- + NA - 
 
decitabine FDA primary indication 
ATC code: L01BC08 Indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de 
novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed 
sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic 
myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
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Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
degarelix FDA primary indication 
ATC code: L02BX02  
A GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency NICE HAS PBAC 
Appraisal date Apr-14 Sep-09 Jul-10 
Comparator LHRH agonists leuproprelin leuproprelin 
Modelled/indirect  comparison No No No 
Basis for classification OS: Committee noted that duration of 
trials was short and were not sufficiently 
powered to detect differences between 
treatment groups. Mixed treatment 
comparison also did not show 
statistically significant differences. Lack 
of evidence to support OS benefit 
compared with LHRH agonists 
 
QoL: Patient experts noted that 
subcutaneous injections of degarelix 
are administered monthly and this 
dosing schedule may be inconvenient 
for some patients compared with 
subcutaneous administration of the 
LHRH agonists every 3 months. The 
manufacturer presented data for 
OS: Not expected to have impact on 
morbidity and mortality. No clinical data 
demonstrating the benefits of this 
product in the treatment of prostate 
cancer 
QoL: Degarelix has not been shown to 
provide any improvement in treated 
patients 
 
Safety: The safety profiles of the two 
treatments were similar, apart from the 
emergence of anti- degarelix 
antibodies. There was no observed 
correlation between emergence of 
these antibodies and the efficacy and 
safety of degarelix after one year of 
treatment 
OS: Submission provided no evidence 
to demonstrate whether outcomes 
observed in the first month of possible 
long-term treatment with degarelix 
would have significant effects on overall 
survival compared with leuproprelin 
 
QoL: NA 
 
Safety: The PBAC noted that there are 
more injection site reactions compared 
with leuprorelin and therefore degarelix 
may not be non-inferior with regards to 
safety. The majority of treatment- 
emergent ADRs were general disorders 
and administration site conditions 
including injection-site reactions which 
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 HRQoL, which was assessed using 
different measures and questionnaires. 
All the SF12 v2 scores were 
comparable across treatment groups 
and study days. 
 
Safety: The Committee heard from the 
patient experts that the safety profile is 
comparable to that of the LHRH 
agonists and the potential benefits of 
outweigh the adverse effects 
associated with it 
 occurred in 73 patients in the degarelix 
240/80 mg group compared with 1 
patient in the leuprorelin arm 
Effects Merged data    
OS increase None established None established None established None established 
QoL change None established No difference No difference NA 
Safety change - No difference No difference - 
 
enzalutamide FDA primary indication 
ATC code: L02BB04  
An androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer who 
have previously received docetaxel. Orphan Status: - 
Licensure: FDA/EMA 
Target: Prostate 
Agency NICE HAS PBAC 
Appraisal date Jul-14 Nov-13 Jul-14 
Comparator placebo placebo abiraterone 
Modelled/indirect  comparison No No Yes 
Basis for classification OS: 4.5-month increase in median OS 
compared to placebo; no statistically 
significant difference compared to 
abiraterone (based on indirect 
comparison) 
OS: 4.8-month increase in median OS 
compared to placebo; Committee noted 
that there was no comparison to active 
comparators 
 
QoL: The fragmented QoL data cannot 
OS: An increase compared to 
abiraterone was not established given 
limitations associated with the indirect 
comparison, though Committee 
accepted claim of non-inferiority 
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 QoL: There was a statistically 
significant difference in QoL for patients 
receiving enzalutamide compared with 
placebo, as measured using Functional 
Assessment of Cancer Therapy- 
Prostate (FACT-P) 
 
Safety: NICE noted that ADRs were 
generally manageable and reversible. 
However, the Committee was aware of 
the increased risk of seizures with 
enzalutamide treatment, and noted that 
the summary of product characteristics 
advises caution when treating people 
with a history of seizures or other 
predisposing factors for seizures 
quantify the impact of enzalutamide on 
the QoL of the patients treated 
 
Safety: Although the Committee refers 
to differences in the safety profile of 
enzalutamide versus placebo, the 
Committee judges neither the strength 
nor direction of difference 
QoL: The comments describe a range 
of benefits from treatment with 
enzalutamide, including improvement in 
survival and QoL 
 
Safety: PBAC considered that the claim 
of non-inferior comparative safety was 
reasonable 
Effects Merged data    
OS increase 4.5-4.8 months ≥ 3 months ≥ 3 months None established 
QoL change + + NA + 
Safety change +/- +/- NA No difference 
 
eribulin FDA primary indication 
ATC code: L01XX41  
A microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at 
least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an 
anthracycline and a taxane in either the adjuvant or metastatic setting. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Breast 
Agency NICE HAS PBAC 
Appraisal date Nov-13 Jul-11 Nov-13 
Comparator TPC TPC TPC 
Modelled/indirect  comparison No No No 
Basis for classification OS: 2.7-month increase in median OS 
compared with TPC in the overall ITT 
population. The Committee considered 
OS: 2.5-month increase in median OS 
(primary endpoint) in the eribulin 
mesylate group versus TPC group 
OS: 2.7-month increase in median OS 
compared with TPC. The PBAC 
acknowledged that eribulin was an 
Downloaded From: http://jamanetwork.com/ by a Harvard University User  on 01/04/2017
Clinical value of cancer medicines 
31 
 
 
 
 that it had not seen sufficient evidence 
to indicate that eribulin offers an 
extension to life of at least 3 months 
 
QoL: The Committee noted that no 
HRQoL data were collected during the 
EMBRACE trial and that data were 
presented from two phase II trials in 
which there was no comparator arm 
 
Safety: It was also aware of the 
importance of the side effects of hair 
loss, grade 3 and 4 peripheral 
neuropathy and febrile neutropenia, all 
of which occurred more frequently with 
eribulin than with TPC. The Committee 
concluded that eribulin was associated 
with a greater overall survival benefit 
compared with TPC but with a less 
favourable toxicity profile 
 
QoL: The impact of the treatment on 
the QoL is not documented; no QoL 
data available 
 
Safety: The incidence of grade 3-4 
adverse events was higher in the 
eribulin mesylate group than those 
treated with TPC 
 
effective drug that offered a modest 
survival benefit at the end of life 
 
QoL: NA 
Safety: The PBAC noted that eribulin 
appeared to cause higher rates of 
adverse events than potential 
comparators. Overall, the PBAC 
considered that the safety profile of 
eribulin is different to vinorelbine with 
higher rates of peripheral neuropathy, 
and worse than best supportive care 
and some other potential comparators 
Effects Merged data    
OS increase 2.5–2.7 months < 3 months < 3 months < 3 months 
QoL change None established NA NA NA 
Safety change - - - - 
 
 
erlotinib FDA primary indication 
ATC code: L01XE03  
Indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least 
one prior chemotherapy regimen. Orphan Status: – 
Licensure: FDA/EMA 
Target: Lung 
Agency NICE HAS PBAC 
Appraisal date Nov-08 Mar-06 Nov-07 
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Comparator No treatment placebo BSC 
Modelled/indirect  comparison No No No 
Basis for classification OS: 2.0-month increase in median OS 
compared to no treatment. Difference in 
benefit with docetaxel is uncertain in the 
absence of direct comparisons 
 
QoL: Committee noted that patients 
may prefer erlotinib treatment to 
docetaxel because it is orally 
administered and they would therefore 
need to spend less time in hospital 
receiving treatment 
 
Safety: Clinical specialists and patient 
experts emphasised erlotinib’s 
favourable toxicity profile, with fewer 
serious AEs reported during treatment 
with erlotinib than with docetaxel 
OS: 2.0-month increase in median OS 
(primary endpoint) compared to 
placebo. No survival benefit in patients 
treated whose tumor EGFR expression 
was negative 
 
QoL: Time to deterioration of the three 
symptoms (cough, dyspnoea and pain) 
was significantly increased in patients 
treated with erlotinib: cough 2.9 
months, dyspnoea 2 months and pain 
approximately 1 month 
 
Safety: The most commonly reported 
undesirable effects in the comparative 
study were diarrhoea and a skin rash. 
The dose was reduced because of 
undesirable effects in 19% of patients 
in the erlotinib group compared with 
2% in the placebo group. Treatment 
was withdrawn from 5% of patients in 
the erlotinib group. Although AE rates 
and incidence is given, overall 
assessment of drug-related change in 
safety is not given by HAS 
OS: Statistically significant differences 
versus BSC regarding all event rates, 
including overall survival. Statistically 
significant differences versus BSC 
regarding all event rates, including 
overall survival. Although exact gain in 
OS is not given, the label refers to 
various, placebo-controlled trials in the 
NEJM (referred to as BSC in a PBAC 
label published in 2006) which indicate 
that gain in OS associated with 
treatment is 2.0 months. 
 
QoL: NA 
 
Safety: Study BR.21 showed that 
erlotinib was associated with 
significantly more rash and diarrhoea 
compared to placebo, although they 
were mild to moderate intensity. There 
was no relevant haematological toxicity 
reported. For PBAC’s comments on 
these results, see Recommendation and 
Reasons 
Effects Merged data    
OS increase 2.0 months < 3 months < 3 months < 3 months 
QoL change + + + NA 
Safety change +/- + NA - 
 
everolimus FDA primary indication 
ATC code: L01XE10 A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with 
sunitinib or sorafenib. Orphan Status: EU (w) 
Licensure: FDA/EMA 
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Target: Renal  
Agency NICE HAS PBAC 
Appraisal date Apr-11 Jan-10 Nov-09 
Comparator BSC placebo BSC 
Modelled/indirect  comparison Yes No No 
Basis for classification OS: More than 3-month increase 
compared to BSC (exact magnitude of 
was uncertain given that it was "based 
on modelled data as opposed to data 
directly observed in the trial"); 
Committee considered a modelled 5.2- 
month increase compared to BSC 
"more plausible" than the 8.2-month 
increase derived by the manufacturer 
 
QoL: Time to deterioration in 
functioning/symptoms was delayed with 
everolimus + BSC by 3.5 months 
compared with placebo + BSC. The 
median time to deterioration according 
to FKSI–DRS score was 7.4 months for 
everolimus + BSC and 3.9 months for 
placebo + BSC. Difference was 
statistically significant 
 
Safety: The Committee noted the 
increased frequency of AEs (including 
serious) associated with everolimus 
treatment. There was a greater 
incidence of AEs (including serious) 
reported in the everolimus + BSC arm 
(40.1%) than the placebo + BSC arm 
(22.6%) 
OS: An increase compared to placebo 
(optimum symptomatic treatments) not 
established as no improvement was 
observed; Committee acknowledged 
that an assessment was difficult "given 
the premature termination of the pivotal 
study and the fact that patients whose 
disease had demonstrably progressed 
were allowed to transfer" 
 
QoL: No improvement was 
demonstrated in the pivotal study 
(QLQ-C30) 
 
Safety: More patients in the everolimus 
group stopped treatment as a result of 
adverse effects than in the placebo 
group 
OS: No statistically significant difference 
was observed compared to BSC 
 
QoL: PBAC considered that the results 
for Karnofsky performance status, 
physical function, and QoL scores 
showed no statistically significant 
differences and performance status 
between everolimus and placebo 
treated patients. However, these results 
are difficult to interpret because of the 
substantial crossover of placebo 
patients to everolimus treatment 
 
Safety: Everolimus has significant on- 
treatment toxicity compared to placebo, 
including increased risk of serious 
infection, non-infectious pneumonitis, 
dyspnea, stomatitis, hyperglycaemia, 
anaemia, lymphopenia as well as 
neurotoxicity 
Effects Merged data    
OS increase 5.2 months ≥ 3 months None established None established 
QoL change + + No difference No difference 
Safety change - - - - 
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gefitinib FDA primary indication 
ATC code: L01XE02  
Indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with 
activating mutations of EGFR-TK. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Lung 
Agency NICE HAS PBAC 
Appraisal date Jul-2010 Nov-2009 Jul-2013 
Comparator paclitaxel + carboplatin paclitaxel + carboplatin paclitaxel + carboplatin 
Modelled/indirect  comparison No No No 
Basis for classification OS: Committee was aware that the OS: Median overall survival did not OS: The data were updated for trials 
analysis of OS was an interim analysis differ between the two groups (18.6 NEJ002 and WJTOG3405, but were still 
of immature data. The Committee noted months in the IRESSA group and 17.3 immature for the WJTOG3405 trial. As 
that a longer progression-free survival months in the comparator group). The seen in the IPASS (paclitaxel + 
may correlate with improved overall overall survival results are not mature carboplatin) and First-SIGNAL (cisplatin 
survival in NSCLC, but there was (number of events not reached) + gemcitabine) trials, there was no 
uncertainty around this  significant difference between the two 
 QoL: quality of life analysis results treatment arms in terms of OS (NEJ002 
QoL: Committee agreed that treatment showed an improvement in the IRESSA HR=0.89; 95% CI: 0.63, 1.24; 
… offers an advantage because it can group in two of the three scales used WJTOG3405: HR=1.19; 95% CI: 0.77, 
be taken at home. Committee accepted (FACT-L and TOI) 1.83) 
the ERG's view that EGFR-TK   
mutation-positive patients who were Safety: No comparative data presented QoL: The PBAC accepted that the 
randomised to receive gefitinib had a clinical benefit of listing gefitinib in 
clinically relevant improvement in patients with EGFR M+ NSCLC as first- 
health-related quality of life and disease line treatment in addition to the current 
symptoms compared with patients listing for second-line treatment is an 
randomised to receive paclitaxel and improvement in quality of life 
carboplatin  
 Safety: Overall, safety profiles varied 
Safety: The Committee concluded that across the treatment arms, but gefitinib 
gefitinib was associated with an appeared to have less serious toxicity 
improved adverse effects profile than platinum-based therapy … the 
compared with platinum-based PBAC accepted that gefitinib appears to 
chemotherapy. Clinical specialists have less serious toxicity than platinum- 
confirms that gefitinib had been shown based doublet chemotherapy 
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 to be well tolerated in clinical practice   
Effects Merged data    
OS increase None established None established None established None established 
QoL change + + + + 
Safety change + + NA + 
 
ibrutinib FDA primary indication 
ATC code: L01XE27  
A kinase inhibitor indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one 
prior therapy. This indication is based on overall response rate. Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
ipilimumab FDA primary indication 
ATC code: L01XC11  
A human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of unresectable or 
metastatic melanoma. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency NICE HAS PBAC 
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Appraisal date Jul-14 Nov-14 Nov-12 
Comparator dacarbazine dacarbazine / temozolomide / vemurafenib Dacarbazine 
Modelled/indirect  comparison No Yes Yes 
Basis for classification OS: 5.7-month increase in mean OS 
compared to dacarbazine when given 
as first-line (2.1-month increase in 
median OS); mean OS was available 
because of the long duration of the trial 
and lack of crossover 
 
QoL: First- and second-line, no HRQoL 
data reported 
 
Safety: Severe, serious, drug-related 
and AEs leading to discontinuation  
were all more frequent in the ipilimumab 
10 mg/kg + dacarbazine group than in 
dacarbazine alone group. In second- 
line treatment, the Committee 
concluded that the ADRs and mortality 
associated with ipilimumab seen in the 
MDX010-20 trial were considerable 
OS: Committee noted that the results of 
an indirect comparison with several 
comparators (dacarbazine, 
temozolomide, and vemurafenib) 
suggested that OS improved with 
ipilimumab, but did not allow for a 
formal conclusion 
QoL: A negative impact on quality of 
life cannot be ruled out mainly because 
of significant side effects experienced. 
No explicit judgment on comparative 
differences in HRQoL given 
 
Safety: The safety data provided in this 
new indication are comparable to the 
safety profile seen to date for this 
specialty 
OS: Committee considered that the 
"magnitude of the incremental benefit of 
ipilimumab remained uncertain" 
compared to dacarbazine as the 
submission was "reliant on extrapolation 
of trial results to a ten-year time horizon" 
 
QoL: NA 
 
Safety: Ipilimumab has a different safety 
profile than BSC (DTIC/fotemustine), 
with irAEs (immune-related adverse 
events) which are manageable and 
controllable. Even though the PBAC 
considers this claim reasonable, it does 
not indicate whether it believes 
differences to be clinically meaningful 
and does not give a value judgment 
Effects Merged data    
OS increase 5.7 months ≥ 3 months Uncertain Uncertain 
QoL change None established NA NA NA 
Safety change - - No difference NA 
 
ixabepilone FDA primary indication 
ATC code: L01DC04  
A microtubule inhibitor, in combination with capecitabine is indicated for treatment of metastatic or locally advanced breast 
cancer in patients after failure of an anthracycline and a taxane. 
Also indicated as monotherapy for treatment of metastatic or locally advanced breast cancer in patients after failure of an 
anthracycline, a taxane, and capecitabine. 
Orphan Status: – 
Licensure: FDA 
Target: Breast 
Agency NICE HAS PBAC 
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Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
lapatinib FDA primary indication 
ATC code: L01XE07  
A kinase inhibitor, indicated in combination with capecitabine, for the treatment of patients with advanced or metastatic breast 
cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and 
trastuzumab. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Breast 
Agency NICE HAS PBAC 
Appraisal date May-10 Jul-08 Nov-07 
Comparator capecitabine monotherapy capecitabine monotherapy capecitabine monotherapy 
Modelled/indirect  comparison No No No 
Basis for classification OS: 2.4-month increase in overall 
median survival; certainly not enough 
evidence that the extension of life 
provided was 3 months or greater 
 
QoL: No HRQoL information presented 
in report 
 
Safety: The lapatinib + capecitabine 
group had a marginally higher incidence 
of diarrhoea and palmar-plantar 
erythrodysaesthesia than the 
capecitabine monotherapy group 
OS: At the cut-off point for the first 
interim analysis, no difference was 
observed between the two treatment 
arms. In view of the premature 
termination of the study, the benefit of 
lapatinib + capecitabine compared with 
capecitabine alone in terms of overall 
survival cannot be evaluated 
 
QoL: The available data are insufficient 
to estimate the impact of lapatinib + 
capecitabine in reducing the morbidity 
and mortality associated with 
metastatic breast cancer and in 
OS: 1.1-week increase in median overall 
survival. However, study was terminated 
early by independent monitoring board, 
and patient crossover. Early termination 
reduces the likelihood of detecting a 
significant difference in overall survival. 
There is some evidence improves 
survival compared to capecitabine 
alone, but full extent of survival benefit  
is not known and is not statistically 
different from comparator treatment 
alone 
 
QoL: NA 
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  improving QoL, compared with the 
current form of management 
 
Safety: Main AEs were often raised in 
the lapatinib + capecitabine arm 
compared with the capecitabine arm, 
including for: diarrhoea, palmar-plantar 
erythrodysaesthesia, nausea, rash, and 
vomiting. However, the HAS does not 
make a judgment as to the statistical or 
clinical significance of these findings 
 
Safety: The overall safety profile of 
lapatinib + capecitabine, in terms of the 
incidence, types and intensities of 
adverse events, appears similar to that 
reported in the published studies for 
different  trastuzumab-containing 
chemotherapies for patients with 
metastatic breast cancer 
Effects Merged data    
OS increase 0.3–2.4 months < 3 months None established Uncertain 
QoL change None established NA NA NA 
Safety change - - NA No difference 
 
lenalidomide FDA primary indication 
ATC code: L04AX04  
Indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic 
syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Sep-14 Nov-14 Mar-13 
Comparator placebo placebo placebo (BSC) 
Modelled/indirect  comparison No No No 
Basis for classification OS: No statistically significant 
difference. Placebo arm could cross 
over to lenalidomide treatment, 
therefore benefit of lenalidomide may 
be underestimated. Lenalidomide could 
indirectly improve OS by improving 
transfusion independence, but this was 
OS: Available clinical data shows better 
cytogenic response but without benefit 
in OS 
 
QoL: Given current therapeutic 
strategies, the available clinical data 
indicates a moderate impact in terms of 
OS: While results did not show 
statistically significant change in OS, 
possibly owing to patient cross-over, the 
PBAC considered that there was a trend 
favoring lenalidomide 
 
QoL: For key results, see Mar 2011 
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 uncertain 
 
QoL: Committee considered the results 
of the MDS-004 study: the rates of 
transfusion independence (at 26 weeks, 
lenalidomide 10 mg: 56.1%, placebo: 
5.9%) and improvements in the FACT- 
An questionnaire (mean change, 
lenalidomide 10 mg: 5.8, placebo: -2.5) 
were significantly better in people 
treated with lenalidomide compared 
with placebo 
 
Safety: Committee was aware that 
lenalidomide may be associated with 
higher rates of venous thrombo- 
embolism than placebo. A higher 
proportion of people in the lenalidomide 
10 mg (95.7%) and 5 mg groups 
(98.6%) had at least 1 drug-related AE 
compared with the placebo group 
(49.3%). However, it heard from the 
clinical specialist and patient experts 
that AEs associated with lenalidomide 
treatment are managed with dose 
interruptions and are generally well 
tolerated. The Committee concluded 
that, although lenalidomide is 
associated with some AEs, these can 
be managed by dose interruptions 
morbidity and mortality and quality of 
life should be expected from 
lenalidomide. The "transferability of test 
results to the practice can be regarded 
as assured" 
 
Safety: The safety profile observed in 
the lenalidomide MDS patients of low 
risk associated with a deletion 5q was 
comparable to that already 
experienced in patients with myeloma. 
Regarding the first 16 weeks of the 
double-blind phase, at least one 
adverse event was observed in all 
patients of lenalidomide group (69 
patients in the 5 mg group and 69 
patients in the 10 mg group) and in 
96% of 67 patients in the placebo 
group 
PSD. PBAC noted clinical meaningful 
change in patients HRQoL after 24 
weeks of treatment with lenalidomide 
and a worsening in placebo patients. 
However, the results were confounded 
due to loss to follow up 
 
Safety: PBAC considered that treatment 
with lenalidomide was associated with 
more toxicity than best supportive care 
and that dose reduction would be 
required to manage side effects in a 
number of patients 
Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
Uncertain 
 
None established 
 
Uncertain 
QoL change + + + NA 
Safety change - - No difference - 
 
 
nelarabine FDA primary indication 
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ATC code: L01BB07  
Indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose 
disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. This use is 
based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit 
have not been conducted. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA Dec-07 NA 
Comparator NA non-comparative NA 
Modelled/indirect  comparison NA Yes NA 
Basis for classification NA OS: Facilitates the use of allografts, 
therefore expected to have an impact 
on morbidity and mortality, which can 
only be low. Because of the uncertainty 
about the tolerability of this drug, 
extrapolation of the trial results to real 
life is uncertain 
QoL: NA 
 
Safety: There are "currently few safety 
data". Safety-related data drawn from 
non-comparative adult and child 
studies 
NA 
Effects Merged data    
OS increase None established NA None established NA 
QoL change None established NA 
NA NA 
Safety change None established NA NA NA 
 
nilotinib FDA primary indication 
ATC code: L01XE08 A kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive 
chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib. Orphan Status: US/EU 
Licensure: FDA/EMA 
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Target: Hematological  
Agency NICE HAS PBAC 
Appraisal date Jan-12 Feb-08 Mar-08 
Comparator non-comparative non-comparative non-comparative 
Modelled/indirect  comparison Yes No Yes 
Basis for classification OS: Clinical trials were non- 
comparative, of short duration and had 
used surrogate outcomes to predict OS. 
The Committee noted the poor quality 
of the evidence base 
 
QoL: No regulatory judgment made on 
comparative differences in HRQoL 
 
Safety: Committee concluded that 
dasatinib and nilotinib are better 
tolerated than imatinib, and that older 
treatments, particularly interferon alfa, 
can be poorly tolerated 
OS: No comparative evaluation of OS 
relative to available treatments 
 
QoL: No comparative data presented 
 
Safety: There are currently few 
safety data. No comparative data 
presented 
OS: Committee does not present any 
conclusion regarding OS benefits. 
Evidence for nilotinib after imatinib and 
dasatinib treatment is from single arm 
open-label nilotinib study for CML-CP 
and CML-AP 
 
QoL: NA 
 
Safety: PBAC noted that whilst nilotinib 
has a different safety profile to both high 
dose imatinib and dasatinib, there is 
considerable uncertainty around the 
claims that nilotinib has significant 
activity after failure of both imatinib and 
dasatinib and that nilotinib has a 
superior safety profile to dasatinib 
Effects Merged data    
OS increase None established None established None established None established 
QoL change None established NA NA NA 
Safety change + + NA NA 
 
obinutuzumab FDA primary indication 
ATC code: L01XC15  
A CD20-directed cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with 
previously untreated chronic lymphocytic leukemia. Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
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Agency NICE HAS PBAC 
Appraisal date Mar-15 Feb-15 Jul-14 
Comparator chlorambucil rituximab / chlorambucil chlorambucil 
Modelled/indirect  comparison No No No 
Basis for classification OS: Obinutuzumab + chlorambucil was 
associated with statistically significantly 
greater OS compared with chlorambucil 
monotherapy. However, the Committee 
acknowledged that the OS data were 
immature 
 
QoL: The clinical expert and patient 
expert acknowledged that some people 
may prefer oral treatment with 
chlorambucil instead of having to attend 
a day unit for intravenous treatment 
with obinutuzumab or bendamustine 
 
Safety: Some people may prefer to 
have obinutuzumab instead of 
bendamustine, because obinutuzumab 
is associated with fewer AEs. The 
Committee took into consideration the 
summary of product characteristics and 
concluded that obinutuzumab had an 
acceptable adverse event profile 
OS: Impact compared to the 
comparator (R-Clb) is not quantifiable 
 
QoL: The impact compared to the 
comparator (R-Clb) is not quantifiable 
 
Safety: Compared to rituximab, the 
incidence of AEs ≥ grade 3 was higher 
in the G-Clb group than in the R-Clb 
group 
OS: PBAC accepted the claim that 
obinutuzumab + chlorambucil is superior 
in terms of comparative effectiveness 
and inferior in terms of comparative 
safety over chlorambucil alone. While 
hazard ratio for OS was not statistically 
significant, the trend was in favor of 
obinutuzumab + chlorambucil and the 
more recent data is approaching 
statistical significance 
 
QoL: Consumer comments captured the 
notion that obinutuzumab provides a 
treatment option for older, less fit 
patients with CLL and prolongs 
remission during which time patients 
can live a "normal life" 
 
Safety: PBAC accepted the 
submission’s claim that obinutuzumab + 
chlorambucil is inferior in terms of 
comparative safety over chlorambucil 
alone 
Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
Uncertain 
 
None established 
 
Uncertain 
QoL change +/− - NA + 
Safety change +/− + - - 
 
ofatumumab FDA primary indication 
ATC code: L01XC10 A CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia 
Downloaded From: http://jamanetwork.com/ by a Harvard University User  on 01/04/2017
Clinical value of cancer medicines 
43 
 
 
 
Orphan Status: US/EU (CLL) refractory to fludarabine and alemtuzumab. The effectiveness of ofatumumab is based on the demonstration of durable 
objective responses. Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Oct-10 Oct-10 Nov-14 
Comparator non-comparative non-comparative chlorambucil 
Modelled/indirect  comparison Yes Yes No 
Basis for classification OS: No data on median OS available 
for patients responding to treatment 
because data were immature. Although 
it was likely that ofatumumab is 
effective based on the observed ORRs, 
and partly based on manufacturer's 
model regarding extensions to life (">5 
months relative to BSC"), it was not 
possible to estimate the size of the 
effect with certainty because of the 
absence of robust and comparative 
evidence and the immaturity of the data 
 
QoL: No HRQoL information presented 
in report. HRQoL had not been 
collected in the pivotal study 
 
Safety: The Committee concluded that 
ofatumumab may be associated with 
AEs, but the extent and impact of these 
was uncertain owing to a lack of robust 
evidence and the lack of a group of 
patients who did not receive 
ofatumumab in the trial 
OS: The quality of the data available is 
not sufficient to allow an evaluation of 
the impact in terms of mortality of the 
medicinal product. Comparison of 
ofatumumab with historical data does 
not allows unbiased evaluation to be 
made of the size of effect, therefore it is 
not considered by the Committee 
 
QoL: NA 
 
Safety: The efficacy and tolerance 
data are limited, as they are drawn 
from a non-comparative phase II study 
OS: No difference was observed in 
direct comparison with chlorambucil, 
which may be due to the limited follow- 
up of the trial for patients with indolent 
CLL. Overall, incomplete and less than 
rigorous comparison of ofatumumab 
with rituximab (modelled evaluation) 
QoL: NA 
 
Safety: PBAC noted no important overall 
differences in adverse events 
Effects Merged data    
OS increase None established None established None established None established 
QoL change None established NA NA NA 
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Safety change None established NA NA No difference 
 
omacetaxine mepesuccinate FDA primary indication 
ATC code: L01XX40  
Adult patients (injection) with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or 
intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate. Orphan Status: US 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
panitumumab FDA primary indication 
ATC code: L01XC08  
Indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following 
fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Orphan Status: - 
Licensure: FDA/EMA 
Target: GI 
Agency NICE HAS PBAC 
Appraisal date Jan-12 Apr-08 Nov-13 
Comparator BSC palliative care cetuximab 
Modelled/indirect  comparison Yes No No 
Basis for classification OS: Approximately 3-month extension OS: An increase compared palliative OS: No statistically significant difference 
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 to life compared to BSC (mean life 
extension estimated to be 2.7 to 3.2 
months after adjusting for patient 
crossover in the trial); no statistically 
significant difference in overall survival 
was observed in the trial 
 
QoL: No HRQoL data presented in 
report 
 
Safety: Committee did not discuss 
specific issues around the AEs to the 
technologies appraised but it was 
aware of the special warnings and 
precautions for use outlined in the 
SPC 
care not established as no statistically 
significant difference was observed 
 
QoL: In light of the available data (just 
one post hoc analysis on subgroups of 
the pivotal study), the impact of 
panitumumab on morbidity, mortality 
and quality of life cannot be quantified 
 
Safety: Safety data are currently 
limited. There is no judgment of 
comparative differences in toxicity 
was observed compared to cetuximab 
(third-line) 
 
QoL: NA 
 
Safety: The PBAC considered the claim 
that panitumumab is non-inferior in 
terms of safety to cetuximab to be 
reasonable in the third-line setting 
where both drugs were used as 
monotherapy 
Effects Merged data    
OS increase 2.7–3.2 months ≥ 3 months None established None established 
QoL change None established NA NA NA 
Safety change None established NA NA No difference 
 
pazopanib FDA primary indication 
ATC code: L01XE11  
A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma. 
Orphan Status:  EU (w) 
Licensure: FDA/EMA 
Target:  Renal 
Agency NICE HAS PBAC 
Appraisal date Feb-11 Jun-13 Mar-12 
Comparator BSC/interferon-alfa placebo/sunitinib BSC/sunitinib 
Modelled/indirect  comparison Yes No Yes 
Basis for classification OS: More than 3-month increase OS: An increase compared to sunitinib OS: No statistically significant difference 
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 compared to BSC (based on RPSFT 
model) and interferon-alfa (based on 
indirect comparison), though exact 
magnitude of increase uncertain; no 
significant difference compared to 
sunitinib based on results from head-to- 
head trial the Committee noted would 
be available in 2012 
 
QoL: For the VEG105192 trial, there 
were no statistically significant 
differences between pazopanib and 
placebo for any of the instruments used 
(European Organisation for Research 
and Treatment of Cancer [EORTC] QoL 
questionnaire – Core 30, EQ-5D, EQ- 
5D-VAS) 
Safety: Committee heard from the 
clinical specialists that the evidence 
presented by the manufacturer 
suggested that pazopanib has a more 
favourable toxicity profile than sunitinib, 
especially in relation to hand-foot 
syndrome. The clinical specialists and 
patient experts were of the opinion that 
pazopanib is a useful option because it 
has a more favourable toxicity profile 
than sunitinib 
not established (first-line) as no 
statistically significant difference was 
observed; Committee noted that non- 
inferiority compared to sunitinib was 
"the subject of serious doubt"; increase 
compared to placebo not established 
as no statistically significant difference 
was observed 
 
QoL: No reliable conclusions could be 
drawn from evaluation scores as to any 
difference between the two treatments. 
In fact, results varied depending on the 
scale used: there was no difference on 
one scale (FACIT-F), although there 
were differences on the FKSI-19 and 
CTSQ scales but with values below the 
threshold for clinical relevance 
 
Safety: For 1st RCC, the safety profile 
differed between the two groups, with 
notably a higher incidence of abnormal 
liver function tests in the pazopanib 
group and a higher incidence of hand- 
foot syndrome in the sunitinib group. 
For 2nd RCC, treatment 
discontinuation due to AEs was twice 
as common in the pazopanib group as 
in the placebo group 
was observed compared to BSC (even 
after adjusting for patient crossover with 
IPCW and RPSFT models); no 
statistically significant difference was 
observed compared to sunitinib (based 
on indirect comparison) 
 
QoL: NA 
 
Safety: PBAC concluded that pazopanib 
has a different side-effect profile to 
sunitinib. Patients taking sunitinib tend 
to experience events such as diarrhoea, 
fatigue, hypertension, mucositis, hand- 
foot syndrome, and myelosuppression; 
patients taking pazopanib tend to 
experience diarrhoea, hypertension and 
liver dysfunction. These differences are 
insufficient to change an overall 
conclusion that pazopanib is non-inferior 
to sunitinib in terms of safety. 
Effects Merged data    
 
OS increase 
Exact gain 
over 3 
months 
uncertain 
 
≥ 3 months 
(Exact gain over 3 months uncertain) 
 
None established 
 
None established 
QoL change None established No difference No difference NA 
Safety change +/− + +/− (1st RCC); − (2nd RCC) = +/− No difference 
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pemetrexed FDA primary indication 
ATC code: L01BA04 In combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either 
unresectable or who are otherwise not candidates for curative surgery. Orphan Status: US/EU (w) 
Licensure: FDA/EMA 
Target: Lung 
Agency NICE HAS PBAC 
Appraisal date Jan-08 Mar-05 Nov-07 
Comparator cisplatin cisplatin cisplatin 
Modelled/indirect  comparison No No No 
Basis for classification OS: 2.8-month increase in median OS 
compared to cisplatin 
 
QoL: Committee noted that there was 
some evidence showing that 
pemetrexed plus cisplatin was 
associated with significant symptomatic 
improvements compared with cisplatin 
alone. Committee agreed that the 
economic analyses may have 
underestimated the overall quality of life 
benefits of pemetrexed in people with 
MPM. Combination treatment appears 
to demonstrate advantages in QoL 
 
Safety: Severe to life-threatening or 
disabling adverse events were 
statistically significantly more frequent 
in patients receiving pemetrexed plus 
cisplatin than in those receiving 
cisplatin alone 
OS: 3.3-month increase in median OS 
compared to cisplatin in subgroup of 
patients fully supplemented with 
vitamins; 2.8-month increase in median 
OS compared to cisplatin in the 
intention-to-treat population 
 
QoL: It was also observed a reduction 
of certain clinical symptoms (dyspnea, 
pain) related to the disease and 
improving lung function 
 
Safety: No comparative data presented 
OS: 2.8-month increase in median OS 
 
QoL: data from the pivotal trial using the 
Patient Lung Cancer Symptom Scale 
(LCSS) were presented. There were 
significant improvements in fatigue, 
dyspnea, pain, symptom distress, 
activity level, and overall LCSS, except 
for hemoptysis, in the pemetrexed+ 
cisplatin treatment arm. Although the 
global QoL scale did not show 
significant changes, the total LCSS as 
an average of all nine items reached a 
statistically significant difference in favor 
of pemetrexed 
 
Safety: Serious AEs occurred more 
frequently in the PMT+cisplatin arm than 
the cisplatin alone arm. Overall, 
frequency of Grade 3/4 laboratory 
toxicity was higher in the PMT+cisplatin 
arm than in the cisplatin alone arm. 
Severe toxicity was uncommon in the 
cisplatin arm, compared to the 
PMT+cisplatin arm where Grade 3⁄4 
neutropenia were the most common 
haematologic toxicities 
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Effects Merged data    
OS increase 2.8–3.3 months < 3 months ≥ 3 months < 3 months 
QoL change + + + + 
Safety change - - NA - 
 
pertuzumab FDA primary indication 
ATC code: L01XC13  
A HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with 
HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic 
disease. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Breast 
Agency NICE HAS PBAC 
Appraisal date NA Jul-13 Mar-14 
Comparator NA trastuzumab + docetaxel trastuzumab + docetaxel 
Modelled/indirect  comparison NA No No 
Basis for classification NA OS: An increase compared to 
trastuzumab + docetaxel was observed 
(by a second interim analysis not 
scheduled in the protocol), but the size 
of the increase was uncertain given 
that median OS had not yet been 
achieved 
 
QoL: The treatment is not expected to 
have any impact on patients’ quality of 
life evaluated using the FACT-B 
questionnaire specific to the disease 
 
Safety: In addition to similar drop-out 
rates from AEs, no difference was seen 
between the two groups (pertuzumab 
vs placebo) as regards the incidence of 
grade 3-4 events 
OS: 15.7-month increase in median OS 
compared to trastuzumab + docetaxel 
 
QoL: PBAC noted strong support for 
pertuzumab received through the 
consumer comments facility expressing 
a range of benefits from treatment 
including improving QoL 
 
Safety: PBAC considered the claim that 
pertuzumab, when used in combination 
with trastuzumab + docetaxel, to be 
"slightly worse" in terms of comparative 
safety. PBAC considered the trial results 
indicated that adding pertuzumab to 
trastuzumab + docetaxel results in 
statistically significant increased toxicity 
in trastuzumab naïve (sensitive) 
compared to trastuzumab + docetaxel 
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Effects Merged data    
OS increase 15.7 months NA Uncertain ≥ 3 months 
QoL change + NA No difference + 
Safety change - NA No difference - 
 
pomalidomide FDA primary indication 
ATC code: L04AX06  
A thalidomide analogue indicated for patients with multiple myeloma who have received at least two prior therapies including 
lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last 
therapy. Approval is based on response rate. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Mar-15 Jan-14 Jul-14 
Comparator standard care high-dose dexamethasone high-dose dexamethasone 
Modelled/indirect  comparison Yes No No 
Basis for classification OS: At least 3-month extension 
compared to standard NHS care (e.g. 
bendamustine) (based on modeled 
data); Committee was "not able to 
judge with any confidence how much 
more effective pomalidomide was 
compared with the current treatment 
options based on the available 
evidence"; nevertheless, the Committee 
was "persuaded that pomalidomide 
extends life for at least 3 months on 
average when compared with standard 
NHS care" based on data modeled data 
that was "not considered robust" 
 
QoL: HRQoL was measured using the 
EORTC questionnaire for patients with 
cancer (QLQ-C30), the EORTC multiple 
myeloma module (QLQ-MY20) and the 
EuroQol-5 dimensions survey (EQ-5D). 
OS: An increase compared palliative 
care not established; median OS was 
not reached in pomalidomide treatment 
arm; Committee noted that 29% of 
patients in the high-dose 
dexamethasone group had received 
pomalidomide because of disease 
progression 
 
QoL: In light of the available clinical 
trial data, no impact in terms of 
morbidity and mortality and QoL is 
expected for the proprietary medicinal 
product pomalidomide in combination 
with dexamethasone 
 
Safety: The most commonly observed 
serious AEs had a comparable 
incidence in the two groups, in 
particular pneumonia and deterioration 
OS: Committee considered that OS 
increased compared to high-dose 
dexamethasone, but the magnitude of 
the increase was redacted 
 
QoL: The PBAC also noted that the EQ- 
5D showed a trend towards improved 
QoL with pomalidomide + LDD 
compared with HDD, noting however 
that the differences in the EQ-5D utility 
index score between treatment arms 
were generally not statistically 
significant 
 
Safety: The PBAC considered that 
pomalidomide has inferior, but 
manageable, safety compared with HDD 
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 Most results presented by the company 
suggest favourable trends with 
pomalidomide compared with 
dexamethasone 
 
Safety: The Committee noted that the 
proportion of patients with adverse 
reactions were similar between those 
taking pomalidomide and high-dose 
dexamethasone 
in general health  
Effects Merged data    
 
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 
 
None established 
 
Uncertain 
QoL change + + No difference + 
Safety change - No difference No difference - 
 
ponatinib FDA primary indication 
ATC code: L01XE24  
A kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic 
myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome 
positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. This 
indication is based upon response rate. 
Orphan Status: EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA Jan-15 Nov-14 
Comparator NA non-comparative dasatinib / nilotinib 
Modelled/indirect  comparison NA Yes Yes 
Basis for classification NA OS: No expected impact in terms of 
morbidity and mortality compared with 
current therapeutic management 
 
QoL: There is no expected impact in 
terms of morbidity and mortality and 
QoL for the specialty ponatinib 
compared with current management 
OS: There is no direct evidence 
available for the comparative efficacy of 
ponatinib vs dasatinib or nilotinib. Based 
on single-arm comparative evidence, it 
is not clear whether ponatinib is better 
or worse than dasatinib or nilotinib in the 
treatment of chronic phase CML 
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Safety: No comparative data available 
QoL: NA 
 
Safety: The PBAC considered that 
ponatinib had an inferior toxicity profile 
to imatinib, dasatinib, and nilotinib, 
especially with regard to serious 
vascular occlusive event 
Effects Merged data    
OS increase None established NA None established None established 
QoL change None established NA No difference NA 
Safety change - NA NA - 
 
pralatrexate FDA primary indication 
ATC code: L01BA05  
A folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell 
lymphoma (PTCL). This indication is based on overall response rate. Orphan Status: EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
 
radium Ra 223 dichloride FDA primary indication 
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ATC code: V10XX03  
An alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant 
prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency NICE HAS PBAC 
Appraisal date NA Apr-14 NA 
Comparator NA Placebo NA 
Modelled/indirect  comparison NA No NA 
Basis for classification NA OS: 2.8-month increase vs placebo 
demonstrated in available studies 
 
QoL: The expected impact on 
preserving QoL remains difficult to 
assess, improved time observed to 
degradation of FACT-P score and the 
EQ-5D utility score are not considered 
clinically relevant and the absence of 
pain assessment. In the absence of 
comparative data versus currently used 
treatments, the expected impact of 
radium-223 dichloride in terms of 
improving QoL compared to those 
treatments currently used cannot be 
quantified 
 
Safety: Although HAS discusses 
several adverse events that were 
observed more frequently in the 
radium-223 dichloride group than in the 
placebo group, the agency does not 
provide an overall assessment of drug- 
related changes in safety 
NA 
Effects Merged data    
OS increase 2.8 months NA < 3 months NA 
QoL change None established NA NA NA 
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Safety change None established NA NA NA 
 
regorafenib FDA primary indication 
ATC code: L01XE21  
A kinase inhibitor indicated for the treatment of metastatic colorectal cancer (CRC) who have been previously treated with 
fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti- 
EGFR therapy. 
Orphan Status: - 
Licensure: FDA/EMA 
Target: GI 
Agency NICE HAS PBAC 
Appraisal date NA May-14 Jul-14 
Comparator NA placebo placebo 
Modelled/indirect  comparison NA No No 
Basis for classification NA OS: 1.4-month increase in median OS 
in regorafenib group relative to placebo 
(primary analysis) 
 
QoL: It is not expected that this and a 
proprietary medicinal product will 
provide any additional impact in terms 
of morbidity and mortality or quality of 
life 
 
Safety: The overall incidence of 
serious adverse events considered as 
being treatment-related was higher in 
the regorafenib group 
OS: 1.4-month increase in median OS. 
PBAC considered that clinical evidence 
from the CORRECT clinical trial was 
mature, there was not cross-over and 
subsequent therapy was relatively 
balanced between treatment groups. 
CORRECT unlikely to have 
underestimated the effectiveness of 
regorafenib compared to BSC. However 
OS benefit not considered to be 
clinically significant 
 
QoL: PBAC noted that no patients in the 
trial had a complete response and that 
EQ-5D data showed no improvement 
compared to BSC 
 
Safety: PBAC agreed that regorafenib 
was inferior in comparative safety to 
BSC and noted severe AEs associated 
with the drug, particularly hepatotoxicity 
and hand-foot skin reactions 
Effects Merged data    
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OS increase 1.4 months NA < 3 months < 3 months 
QoL change None established NA No difference No difference 
Safety change - NA - - 
 
romidepsin FDA primary indication 
ATC code: L01XX39  
A histone deacetylase (HDAC) inhibitor indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have 
received at least one prior systemic therapy. Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
ruxolitinib FDA primary indication 
ATC code: L01XE18  
A kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary 
myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Orphan Status: US / EU (w) 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date Jun-13 Jan-13 Jul-13 
Comparator BSC placebo BSC (hydroxyurea and placebo) 
Modelled/indirect  comparison Yes No Yes 
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Basis for classification OS: The Committee concluded that it 
was plausible that ruxolitinib could offer 
a survival benefit. However, the reason 
for this benefit remained unclear 
 
QoL: The Committee noted that in 
COMFORT-I significantly more patients 
treated had a 50% or more reduction in 
total symptom score than those on 
placebo, and that there was a 
significantly greater reduction in mean 
change from baseline total symptom 
score with ruxolitinib than placebo. 
 
Safety: The Committee concluded that 
ruxolitinib did have a negative impact 
on haematological outcomes in the 
short term, but agreed that these were 
manageable 
OS: The impact of the treatment on OS 
and leukaemic transformation cannot 
be evaluated at present because of the 
small number of events reported 
 
QoL: Ruxolitinib is expected to have a 
low impact on the morbidity of patients 
treated. However, the impact of 
treatment on quality of life is difficult to 
evaluate (several reasons given) 
 
Safety: The overall incidence of 
serious adverse effects was similar in 
the treatment groups in the two pivotal 
studies at around 30%. 
OS: PBAC accepted the clinical claim of 
superior efficacy likely in OS, although 
the magnitude of the survival benefit is 
uncertain due to high number of cross- 
over and confounding factors 
 
QoL: PBAC accepted the claim of 
superior efficacy demonstrated in spleen 
response and QoL measures 
 
Safety: PBAC did not accept the claim 
for equivalence in comparative safety. 
Patients experienced significantly more 
drug-related AEs than patients treated 
with either BAT (in COMFORT-II) or 
placebo (in COMFORT-I). There were 
also significantly more cases of 
thrombocytopenia and anaemia in 
ruxolitinib treated patients compared to 
BAT treated patients in COMFORT-II 
Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
Uncertain 
 
None established 
 
Uncertain 
QoL change + + NA + 
Safety change - - No difference - 
 
sipuleucel-T FDA primary indication 
ATC code: L03AX17  
An autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic 
castrate resistant (hormone refractory) prostate cancer. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency NICE HAS PBAC 
Appraisal date Feb-15 NA NA 
Comparator BSC NA NA 
Downloaded From: http://jamanetwork.com/ by a Harvard University User  on 01/04/2017
Clinical value of cancer medicines 
56 
 
 
 
Modelled/indirect  comparison No NA NA 
Basis for classification OS: 4.0-month median extension 
compared to BSC (based on meta- 
analysis of three trials) in subgroup of 
patients who had not previously 
received chemotherapy; two of the 
three trials showed that sipuleucel-T 
extended life, including the pivotal trial 
with a 4.1-month increase in median 
OS; Committee concluded that "it would 
be reasonable to assume that 
sipuleucel-T and abiraterone had 
similar effectiveness in prolonging 
overall survival" (based on indirect 
comparison). 
QoL: Patient organisations expected 
sipuleucel-T to reduce pain, improve 
mental and physical health, and offer an 
additional treatment option at an early 
stage of disease. The Committee 
concluded that patients would like to 
have the option of having treatment with 
sipuleucel-T within the NHS. 
 
Safety: The Committee noted that the 
European public assessment report 
stated that sipuleucel-T is considered 
less toxic than other therapies (such as 
abiraterone, enzalutamide, docetaxel 
and cabazitaxel) that are currently used 
for treating metastatic hormone- 
resistant prostate cancer 
NA NA 
Effects Merged data    
OS increase 4.0 months ≥ 3 months NA NA 
QoL change + + NA NA 
Safety change + + NA NA 
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sorafenib FDA primary indication 
ATC code: L01XE05  
Indicated for the treatment of patients with advanced renal cell carcinoma. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Renal 
Agency NICE HAS PBAC 
Appraisal date Aug-09 Sep-06 Mar-08 
Comparator BSC placebo BSC 
Modelled/indirect  comparison Yes No No 
Basis for classification OS: More than 3-month increase 
compared to BSC was "likely" for 
people in whom immunotherapy has 
failed (second-line), though exact 
magnitude was uncertain; trial was 
"terminated early, on ethical grounds, 
after an independent review decided 
that sorafenib should be offered to 
participants who were receiving 
placebo" 
 
QoL: No HRQoL difference between 
placebo and sorafenib groups in mean 
FACT-G physical well-being score, nor 
any significant difference in mean 
FKSI−10 total score over the first 32 
weeks of treatment. However, median 
time to health status deterioration, as 
defined by a four-point or more drop in 
FKSI-10 total score, was significantly 
greater than placebo. Those who had 
received sorafenib scored significantly 
better on the following items of the 
FKSI-15 index: coughing; fever; worry 
about their disease; ability to enjoy life. 
 
Safety: associated with more AEs than 
OS: An increase compared to placebo 
not established (second-line); median 
OS was not reached in the sorafenib 
group before patients receiving placebo 
were allowed to switch to sorafenib on 
the basis of "encouraging" progression- 
free survival results 
 
QoL: After 24 weeks of treatment, an 
improvement was observed: in the 
FKSI-10 score (44% in sorafenib 
versus 22% in placebo); in the FACT-G 
score (47% in sorafenib versus 21% in 
placebo). According to the results of 
clinical trials sorafenib is expected, in 
theory, to have a moderate effect on 
morbidity, mortality and quality of life. 
 
Safety: No Committee evaluation 
provided to describe comparative 
differences in safety 
OS: No statistically significant difference 
was observed compared to BSC, though 
Committee noted the influence that 
patient crossover had on the ability of 
the submission to demonstrate efficacy 
in terms of OS; Committee agreed that 
trial data suggested increase in 
progression-free survival as second-line 
treatment but "considered that the 
clinical importance of this gain had not 
been demonstrated…as a surrogate to 
predict future survival gain" 
 
QoL: NA 
 
Safety: PBAC noted that sorafenib is 
associated with a variety of AEs 
including dermatologic and 
gastrointestinal events, hypertension, 
sensory neuropathy, and neutropenia. 
Additionally, a six-fold increase in 
cardiac ischaemia/infarction was found 
in Trial 11213 for sorafenib treated 
patients compared to placebo. 
Diarrhoea, rash, fatigue, hand-foot 
syndrome, alopecia and nausea were 
reported in >20% patients 
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 BSC, particularly hand–foot skin 
reactions and hypertension. A 
significantly greater number of people 
reported ‘bothersome side effects of 
treatment’ than those receiving placebo. 
Skin rashes, hypertension, diarrhoea 
and hand–foot syndrome were more 
common in the sorafenib arm. 
  
Effects Merged data    
 
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 
 
None established 
 
None established 
QoL change + + + NA 
Safety change - - NA - 
 
sunitinib FDA primary indication 
ATC code: L01XE04  
Indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. 
Aso indicated for the treatment of advanced renal cell carcinoma. Approval for advanced renal cell carcinoma is based on 
partial response rates and duration of responses. There are no randomized trials of sunitinib demonstrating clinical benefit 
such as increased survival or improvement in disease-related symptoms in renal cell carcinoma. 
Orphan Status: EU 
Licensure: FDA/EMA 
Target: Renal 
Agency NICE HAS PBAC 
Appraisal date Sept-09 (GIST) Mar-09 (RCC) 
Sept-06 (GIST) 
May-07 (RCC) 
Jul-09 (GIST) 
Jul-08 (RCC) 
Comparator BSC (GIST) / interferon-alfa (RCC) 
BSC (GIST) / 
interferon-alfa (RCC) BSC 
Modelled/indirect  comparison Yes No Yes 
Basis for classification OS: More than 3-month increase 
compared to BSC as GIST treatment 
(7.8 months based on RPSFT model); 
more than 3-month increase compared 
to interferon-alfa as first-line RCC 
treatment (10 months according to 
model based on "Committee's preferred 
assumptions") 
OS: An increase compared to placebo 
not established in GIST treatment given 
that median OS was not reached in 
both treatment arms; increase not 
established compared to interferon-alfa 
in first-line RCC treatment as median 
OS was not reached in either treatment 
arm before patients receiving 
OS: Committee considered that the 
magnitude of increase compared to 
BSC for treatment of GIST was 
"uncertain", noting that the 7.8-month 
survival benefit estimated by the RPSFT 
model "may be an overestimate"; no 
statistically significant difference was 
observed compared to interferon-alfa for 
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QoL: More than 75% of people 
completed the EQ-5D questionnaire at 
each time point and there were no 
statistically significant differences 
reported. For RCC, overall results for 
HRQoL (total score and all subscales) 
were significantly better in the sunitinib 
arm compared with the IFN-α arm. 
 
Safety: For GIST, treatment-related 
AEs and serious AEs were more 
common in the sunitinib arm (83%) than 
in the placebo arm (59%). For RCC, the 
frequency of adverse events associated 
with sunitinib is comparable to that 
associated with IFN-α monotherapy. A 
total of 8% of participants receiving 
sunitinib discontinued treatment 
because of adverse events compared 
with 13% in the IFN-α arm. 
interferon-alfa were allowed to cross 
over to sunitinib based on progression- 
free survival results 
 
QoL: For GIST, NA. For RCC, a 
moderate theoretical impact may be 
expected of sunitinib in terms of 
reducing morbidity and improving 
quality of life in comparison to 
interferon alpha, as a first-line 
treatment. Statistically and clinically 
significant improvement in QoL, 
analysed through 3 FACT-G, FKSI and 
EQ-5D questionnaires, was observed 
in the sunitinib group compared to the 
interferon alpha group 
Safety: For GIST, no regulatory 
judgment is given on the comparative 
differences in safety across groups. For 
RCC, Grade III AEs were more 
frequent in the sunitinib group 
compared to IFN-α arm 
treatment of RCC was observed, though 
Committee "acknowledged that because 
patients that progressed were allowed to 
cross-over this would bias later overall 
survival analyses towards the null, 
thereby underestimating the likely true 
difference between the therapies" 
 
QoL: NA 
 
Safety: For GIST, sunitinib is described 
as inferior in terms of comparative 
safety over placebo. For RCC, the 
PBAC noted the increase in AEs with 
sunitinib over BSC/placebo. Of 
particular concern to the PBAC was 
more recent evidence of cardiac side 
effects of ischemia and heart failure 
Effects Merged data    
 
OS increase 
7.8 months 
(GIST); 
10 months 
(RCC) 
 
≥ 3 months 
 
None established 
 
Uncertain 
QoL change + No Difference (GIST); + (RCC) = + NA (GIST); + (RCC) = + NA (GIST); NA (RCC) = NA 
Safety change - – (GIST); No Difference (RCC) = − NA (GIST); − (RCC) = − − (GIST); − (RCC) = − 
 
tegafur/gimeracil/oteracil FDA primary indication 
ATC code: L01BC53  
Indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin. 
Orphan Status:  EU (w) 
Licensure: EMA 
Target: GI 
Agency NICE HAS PBAC 
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Appraisal date NA Oct-12 NA 
Comparator NA fluorouracil (5-FU) / cisplatin NA 
Modelled/indirect  comparison NA No NA 
Basis for classification NA OS: There was very little difference in 
median OS (primary endpoint) between 
the two groups: 8.6 months in the 
TEYSUNO group vs 7.9 months in the 
5-FU group (HR = 0.92, 95% CI: [0.80; 
1.05]). The median overall survival 
(primary endpoint) was similar across 
the two groups. As this was a 
superiority study, the primary objective 
was not achieved 
 
QoL: the overall FACT-Ga score, which 
evaluates quality of life, was also 
similar between the two groups. 
Available data do not show ... the 
improvement in quality of life 
 
Safety: Similar overall incidence of AEs 
of any grade across both groups. 
Treatment stopped due to AE in 10.7% 
of treated patients vs 14.4% of 
comparator patients. Incidence profile 
for AEs were different between groups, 
with treatment producing greater 
number of AEs in some cases, and 
comparator producing greater number 
of AEs in other cases. However, the 
primary superiority objective was not 
achieved (OS) … the results for the 
secondary endpoints, including safety, 
were of an exploratory nature and did 
not allow any conclusions to be drawn” 
NA 
Effects Merged data    
OS increase None established NA None established NA 
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QoL change None established NA No difference NA 
Safety change None established NA No difference NA 
 
temsirolimus FDA primary indication 
ATC code: L01XE09  
A kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Renal 
Agency NICE HAS PBAC 
Appraisal date Aug-09 Feb-08 Jul-08 
Comparator interferon-alfa interferon-alfa BSC 
Modelled/indirect  comparison No No Yes 
Basis for classification OS: 3.6-month increase in median OS 
 
QoL: Participants receiving 
temsirolimus had a significantly longer 
time in both TWiST and Q-TWiST 
health states compared with 
participants receiving IFN-α alone 
 
Safety: The frequency of treatment- 
related toxic events associated with 
bevacizumab plus IFN-α, sunitinib and 
temsirolimus appears to be comparable 
or slightly better than IFN-α, based on 
the data reported in these trials 
OS: 3.6-month increase in median OS 
 
QoL: The available data are too limited 
for an evaluation of the product’s 
impact on quality of life 
 
Safety: Grades 3–4 adverse effects 
were more common in the interferon 
alpha arm 
OS: Committee considered "there was 
uncertainty about the magnitude of the 
treatment effect of temsirolimus 
compared with BSC" (based on indirect 
comparison); Committee was aware of 
the 3.6-month increase in median OS 
compared to IFN-α but did not consider 
IFN-α to be an appropriate comparator 
 
QoL: PBAC considered that there was 
uncertainty regarding the effect of 
temsirolimus on QoL, as the two trials in 
the submission used different QoL 
instruments 
 
Safety: PBAC noted that AEs occurred 
at a significantly greater frequency in 
temsirolimus-treated patients compared 
to IFN-α patients and concluded that the 
profile of side effects for was different to 
I IFN-α, rather than that temsirolimus 
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   was better tolerated than IFN-α. 
However, PBAC considered that the 
submission did not consider the relative 
harms in comparison with BSC, 
including their impact on incremental 
QALYs and cost-effectiveness 
Effects Merged data    
OS increase 3.6 months ≥ 3 months ≥ 3 months Uncertain 
QoL change + + NA NA 
Safety change + + + NA 
 
tositumomab FDA primary indication 
ATC code: V10XA53 Tositumomab and Iodine-131. Tositumomab is indicated for the treatment of patients with CD20 positive, follicular, non- 
Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following 
chemotherapy. 
Orphan Status: US/EU (w) 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect  comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
 
trabectedin EMA primary indication 
ATC code: L01CX01 Indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, 
or who are unsuited to receive these agents. Orphan Status: – 
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Licensure: EMA  
Target: Soft Tissue 
Agency NICE HAS PBAC 
Appraisal date Feb-2010 Apr-2008  
Comparator BSC non-comparative NA 
Modelled/indirect  comparison Yes No NA 
Basis for classification OS: Median OS was 13.9 months (95% 
CI 12.5 to 18.6). The Committee 
concluded that the use of historical 
controls (BSC) was appropriate. The 
manufacturer reported increased 
median OS over historical control 
patients treated with ifosfamide 6.6 
months (95% CI 5.0 to 9.0), 
dacarbazine 6.6 months (95% CI 4.3 to 
8.4) and etoposide 6.3 months (95% CI 
4.4 to 8.9). Although the Committee 
“considered the clinical effectiveness 
data presented by the manufacturer, 
and noted the median OS for patients 
randomised to the licensed dosage of 
trabectedin exceeded that for patients 
receiving BSC”, it does not indicate 
specify the exact gain in OS 
 
QoL: No comparative HRQoL data 
presented 
 
Safety: The Committee heard from the 
clinical specialist and patient experts 
that there were fewer, less severe and 
less frequent AEs than with the other 
agents. It understood that the AEs 
associated with trabectedin were 
manageable, but nevertheless 
important, as with other chemotherapy 
agents used to treat soft tissue 
sarcoma. 
OS: There was no difference between 
the two groups with regard to median 
overall survival time: 13.9 months in the 
group receiving treatment once every 
three weeks versus 10.8 months in the 
group receiving treatment every week 
 
QoL: No comparative evidence 
provided 
 
Safety: No comparative evidence 
provided 
NA 
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Effects Merged data    
 
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain over uncertain) 
 
None established 
 
NA 
QoL change No difference No difference NA NA 
Safety change + + NA NA 
 
trametinib FDA primary indication 
ATC code: L01XE25  
A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or 
V600K mutations as detected by an FDA-approved test. Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency NICE HAS PBAC 
Appraisal date NA NA Nov-14 
Comparator NA NA dabrafenib 
Modelled/indirect  comparison NA NA No 
Basis for classification NA NA OS: PBAC was satisfied that trametinib 
+ dabrafenib, is more effective than 
dabrafenib alone, however the size of 
the incremental treatment effect is still 
uncertain, particularly for OS 
 
QoL: Report recalls consumer 
comments remarking on some benefits, 
including ability to return to work 
 
Safety: PBAC considered that the 
revised claim of different, but no worse 
comparative safety of trametinib + 
dabrafenib to dabrafenib monotherapy 
was reasonable, noting a decrease in 
rate of cutaneous hyperproliferative 
events and photosensitivity, but 
increase in rate of pyrexia and ejection 
fraction decrease 
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Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
NA 
 
NA 
 
Uncertain 
QoL change + NA NA + 
Safety change None established NA NA No difference 
 
vandetanib FDA primary indication 
ATC code: L01XE12  
A kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with 
unresectable locally advanced or metastatic disease. Orphan Status: US / EU (w) 
Licensure: FDA / EMA 
Target: Thyroid 
Agency NICE HAS PBAC 
Appraisal date NA Jun-12 NA 
Comparator NA Placebo NA 
Modelled/indirect  comparison NA No NA 
Basis for classification NA OS: Did not differ between the two 
groups during the analysis of the 
progression-free survival 
 
QoL: Impact is not measurable 
 
Safety: The Committee indicated that 
during the double-blind treatment 
period, treatment was stopped due to 
adverse events for 12% of patients in 
the vandetanib arm and 3% of patients 
in the placebo arm. Grades ≥ 3 events 
involved 55% of patients in the 
vandetanib group and 24% of patients 
in the placebo group. However, the 
Committee did not provide an overall 
assessment of comparative changes in 
drug-related safety 
NA 
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Effects Merged data    
OS increase None established NA None established NA 
QoL change None established NA NA NA 
Safety change None established NA NA NA 
 
vemurafenib FDA primary indication 
ATC code: L01XE15  
A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E 
mutation as detected by an FDA-approved test. Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency NICE HAS PBAC 
Appraisal date Dec-12 Oct-12 Mar-13 
Comparator dacarbazine dacarbazine dacarbazine 
Modelled/indirect  comparison No No No 
Basis for classification OS: 3.3-month increase in median OS; 
Committee "agreed it that it was 
appropriate to adjust the OS results…to 
control for switching using statistical 
modelling or other techniques" but 
"agreed that any estimate obtained 
using these techniques would be 
subject to uncertainty" 
 
QoL: The Committee agreed with the 
manufacturer's assumption of a higher 
utility value for progression-free 
survival, given its improved clinical 
profile, including oral administration 
compared with intravenous 
administration for dacarbazine 
 
Safety: Treatment-related AEs were 
OS: 3.6-month increase in median OS 
compared to dacarbazine (based on 
follow-up OS analysis not scheduled in 
protocol); 1.5-month increase in 
median OS compared to dacarbazine 
(based on OS analysis scheduled in 
protocol) 
 
QoL: Although HAS indicates that a 
negative impact on quality of life cannot 
be ruled out, particularly in view of the 
safety problems encountered, there is 
no indication that it believes that 
worsened QoL is most likely outcome. 
The statement that worsened QoL can 
occur does not provide definitive proof 
one way or the other 
OS: 3.3-month increase in median OS 
compared to dacarbazine (without 
censoring at crossover); 3.9-month 
increase in median OS compared to 
dacarbazine (with censoring at 
crossover); Committee considered “the 
true estimate" of OS gain would lie 
between those two points 
 
QoL: NA 
 
Safety: The PBAC concluded that 
vemurafenib and DTIC have different 
toxicity profiles, with vemurafenib being 
associated with manageable toxicity. 
PBAC also noted that dabrafenib has a 
preferable toxicity profile as evidenced 
by fewer and less extensive dose 
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 recorded for more people who received 
vemurafenib, may be explained by the 
fact that they stayed on treatment 
longer than those on dacarbazine 
Safety: Safety data is limited due to the 
short follow-up period, especially in the 
pivotal study 
intensity reductions and by favourable 
differences in rates for AEs such as 
photosensitivity, cutaneous squamous 
cell carcinoma – but not pyrex 
Effects Merged data    
OS increase 3.3–3.9 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + NA NA 
Safety change - - NA NA (dacarbazine); − (dabrafenib) = − 
 
vinflunine EMA primary indication 
ATC code: L01CA05  
Indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the 
urothelial tract after failure of a prior platinum-containing regimen. 
Orphan Status:  – 
Licensure: EMA 
Target:  Bladder 
Agency NICE HAS PBAC 
Appraisal date Jan-2013 Dec-2009 Nov-2011 
Comparator BSC BSC BSC 
Modelled/indirect  comparison No No No 
Basis for classification OS: The Committee noted that the 
difference between the study arms was 
not statistically significant for the ITT 
population, but was significant for the 
eligible ITT population ... It considered 
that the results from the ITT population 
were the most appropriate basis for its 
deliberations because randomisation 
had not been broken. It concluded that 
the extent of clinical effectiveness of 
vinflunine compared with BSC had not 
been conclusively demonstrated 
because of the uncertainty of the overall 
survival results 
OS: The study objective was not 
reached in the ITT population: median 
overall survival was 6.9 months (95% 
CI [5.7 – 8.0 months]) in the JAVLOR 
arm versus 4.6 months (95% CI [4.1 – 
7.0 months]) in the comparator arm 
(RR= 0.88; 95% CI [0.69 – 1.12], NS). 
Two other types of analyses 
(multivariate, eligible ITT) discussed, 
but focus given on describing results 
for ITT population 
 
QoL: There was no difference in the 
quality of life assessment and clinical 
benefit between the two [study] arms. 
OS: The PBAC noted that the increment 
is uncertain and, at best, is between 2.3 
(ITT) and 2.6 months (eligible ITT) … 
the selection of the eligible ITT 
population was considered highly 
uncertain … The PBAC agreed that the 
ITT population should be used in 
considering the effectiveness of 
vinflunine. The PBAC accepted that 
vinflunine may be superior in terms of 
comparative efficacy over BSC although 
the magnitude of the overall survival 
gain is uncertain (less than 3 months) 
 
QoL: No comparative data presented 
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 QoL: There were no statistically 
significant differences in overall EORTC 
QLQ-C30 global health status score 
between the two arms (p=0.658). [The 
Committee] noted that there were no 
significant differences in HRQoL 
between patients receiving vinflunine 
and those receiving BSC alone 
Safety: Grade 3 or 4 toxicities relating 
to neutropenia, anaemia and 
constipation occurred in 50%, 19% and 
16% respectively of patients in the 
vinflunine arm of study 302, compared 
with 1%, 8% and 1% of patients 
respectively in the best supportive care 
arm. Febrile neutropenia occurred in 
6% of patients receiving vinflunine 
(none in the best supportive care arm). 
The Committee concluded that there 
were concerns about the tolerability of 
vinflunine 
 
Safety: Treatment discontinuations 
more likely in the vinflunine arm 
compared with BSC alone arm. Grade 
3-4 neutropenia and anaemia was 
higher in treatment arm. Higher 
incidence of non-haematological AEs 
reported in treatment arm. 
 
Safety: AEs significantly more frequent 
in treatment arm included abdominal 
pain, constipation, diarrhea, nausea, 
stomatitis, vomiting, among others. 
Grade III/IV AEs experienced more 
frequently included abdominal pain, 
constipation, nausea, vomiting, fatigue, 
among others. One death directly 
related to vinflunine, though 6% in 
vinflunine and 1% in BSC died within 30 
days of final dose. PBAC noted that 
rates of AEs were higher in the 
treatment arm than in the BSC alone 
arm, and that the pattern of AE and 
serious AEs suggested very high levels 
of toxicity. 
Effects Merged data    
 
OS increase 
Exact 
magnitude 
uncertain 
 
None established 
 
None established 
 
Uncertain 
QoL change None established No difference No difference NA 
Safety change - - - - 
 
vismodegib FDA primary indication 
ATC code: L01XX43  
A hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally 
advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not 
candidates for radiation. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency NICE HAS PBAC 
Appraisal date NA Dec-13 NA 
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Comparator NA non-comparative NA 
Modelled/indirect  comparison NA No NA 
Basis for classification NA OS: In light of the available clinical trial 
data in a non-comparative phase II 
study, an impact in terms of morbidity is 
not expected. In the efficacy trial 
(ERIVANCE), median OS was deemed 
not evaluable in the mBCC or laBCC 
cohorts 
 
QoL: In light of the available clinical 
trial data, an impact in terms of 
morbidity or QoL is not expected 
 
Safety: No comparative data presented 
NA 
Effects Merged data    
OS increase None established NA None established NA 
QoL change None established NA No difference NA 
Safety change None established NA NA NA 
 
vorinostat FDA primary indication 
ATC code: L01XX38  
A histone deacetylase (HDAC) inhibitor indicated for: treatment of cutaneous manifestations in patients with cutaneous T-cell 
lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Orphan Status: US 
Licensure: FDA/EMA 
Target: Hematological 
Agency NICE HAS PBAC 
Appraisal date NA NA Mar-11 
Comparator NA NA BSC 
Modelled/indirect  comparison NA NA No 
Basis for classification NA NA OS: No survival data are available from 
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   study P001 or from the non-comparative 
chemotherapy studies. Quality of data is 
extremely limited. Vorinostat has 
superior efficacy to palliative care, 
however, no conclusion can be reach 
with respect to other available therapies 
 
QoL: NA 
 
Safety: The PBAC agreed that 
vorinostat has significant toxicities, and 
is inferior in safety to palliative care. 
However, expert testimony suggests it is 
less toxic than cytotoxic chemotherapies 
Effects Merged data    
OS increase None established NA NA None established 
QoL change None established NA NA NA 
Safety change +/- NA NA – (placebo); + (chemotherapy) = +/− 
 
ziv-aflibercept FDA primary indication 
ATC code: L01XX44  
In combination with 5-fluorouracil, leucovorin, irinotecan- (FOLFIRI) indicated for metastatic colorectal cancer (mCRC) that is 
resistant to or has progressed following an oxaliplatin-containing regimen. Orphan Status: – 
Licensure: FDA/EMA 
Target: GI 
Agency NICE HAS PBAC 
Appraisal date Mar-14 Jul-13 Jul-13 
Comparator placebo placebo placebo 
Modelled/indirect  comparison Yes No No 
Basis for classification OS: 1.4-month increase in median OS. OS: 1.4-month increase in median OS OS: 1.4-month increase in median OS 
The Committee was not satisfied that  compared to placebo for the K-RAS 
estimates produced by the model were QoL: The expected additional impact of mutant patient population. The PBAC 
sufficiently robust to accept that the 3- this medicinal product in terms of considered this survival gain to be 
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 month life extension criterion is fulfilled 
 
QoL: Although the Committee, echoing 
comments from a patient expert, would 
have liked the manufacturer to have 
collected trial data on HRQoL, the 
Committee noted that patients consider 
therapies such as ziv-aflibercept to 
improve QoL compared with 
chemotherapy 
 
Safety: The Committee concluded that 
treatment with aflibercept + ziv- 
aflibercept was associated with a 
considerable burden of AEs, but that, 
being a new treatment, less is known 
about its AE profile than for other 
available treatments. 
morbidity and mortality and QoL can 
only be very small 
 
Safety: Comparing ziv-aflibercept arm 
to placebo arm, frequency of treatment 
discontinuations due to AEs was 
greater 
modest and the clinical relevance and 
importance to be doubtful 
 
QoL: NA 
 
Safety: PBAC considered the claim that 
ziv-aflibercept is non-inferior in terms of 
comparative safety over cetuximab to 
not be a reasonable assumption, 
considering treatment to be potentially 
worse in comparative harms 
Effects Merged data    
OS increase 1.4 months < 3 months < 3 months < 3 months 
QoL change + + No difference NA 
Safety change - - - - 
 
Source: Authors’ analysis of data from sources identified in the “Methods” section 
Notes: ‘+’ denotes improvement; ‘−’ denotes reduction; ‘+/−’ denotes mixed evidence. Orphan drug status obtained from Orphanet for the US and EU, with withdrawn, (w). 
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eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, 
sorted by magnitude of clinical benefits 
 
 
 
 
Source: Authors’ analysis of data from sources identified in the “Methods” section 
 
Notes: Number of cancer drugs assigned to each level of clinical benefit by each HTA agency. To compare regulatory practices 
across each clinical benefit, the cancer drug sample was restricted to those drugs that were evaluated for that clinical benefit by 
all three HTA agencies. For the purposes of comparison, drugs deemed to increase OS by some unquantifiable increase of 
greater than or equal to 3 months were here grouped with drugs that were associated with a quantifiable increase of greater 
than or equal to 3 months. 
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eTable 3. Interagency agreement – Krippendorff’s alpha coefficients 
 
 
Rater 
Overall Survival Quality of Life Safety 
Entire 
sample 
! = ≥3 
months 
Entire 
sample 
! = 
Improvement 
Entire 
sample 
! = 
Improvement 
Ordinal  
NICE + HAS + PBAC 0.380235 0.632742 0.608365 0 0.230789 -0.143208 
NICE + HAS 0.316244 0.525054 0.608365 0 0.592507 0.127778 
NICE + PBAC 0.233290 0.775789 -0.055263 – -0.033927 -0.439335 
HAS + PBAC 0.618591 0.560272 0.547619 1 -0.046384 0.081633 
Nominal  
NICE + HAS + PBAC 0.354930 0.475309 0.535817 0 0.285894 0.126514 
NICE + HAS 0.319274 0.412811 0.549839 0 0.508850 0.396648 
NICE + PBAC 0.343593 0.618462 -0.027027 – 0.205556 0.080808 
HAS + PBAC 0.403390 0.354115 0.547619 1 0.174041 0.080808 
Units 186 117 186 117 186 147 
 
Source: Authors’ analysis of data from sources identified in the “Methods” section 
 
Notes: Krippendorff’s alpha coefficients were used to measure interagency agreement on the level of clinical benefit assessed by 
each agency. Krippendorff’s alpha coefficients were measured for different agency pairings (left) and for either the entire sample 
(“Entire Sample”) or for drugs that were not associated with an increase in overall survival of greater than or equal to 3 months (“!= 
≥ 3 months”) or with an improvement in quality of life or safety (“!= Improvement”). Given the inherent order in the clinical benefit 
classifications used (OS: ≥3 months, <3 months, increase but magnitude uncertain, no increase; QoL, safety: improvement, mixed 
evidence, reduction, no difference), base case Krippendorff's alpha coefficient were calculated by modeling clinical benefit data as 
an ordinal variable (top). To test for robustness, sensitivity analyses modelled the data as a nominal variable (bottom). For the 
purposes of comparison, drugs deemed to increase OS by some unquantifiable increase of greater than or equal to 3 months 
were here grouped with drugs that were associated with a quantifiable increase of greater than or equal to 3 months. 
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eMethods 
 
Drug inclusion/exclusion criteria 
Drugs that did not directly treat cancer, or which were intended to manage symptoms, pain, or the side 
effects of active treatment, were excluded. Oncology drugs approved by the US Food and Drug 
Administration (FDA) between 2003-2010 were obtained the FDA’s Drugs@FDA registry1 and from 
Roberts and colleagues,2 with two exclusions: plerixafor, on the grounds it does not directly treat cancer 
and palifermin, on the grounds that it is primarily intended to manage side effects. Drugs approved 
between 2011-2013 were obtained by reviewing all novel FDA drug approvals for 2011,3 2012,4 and 
2013,5 and applying inclusion/exclusion criteria. FDA recommended indications were obtained through  
the Drugs@FDA registry. Initial approvals for medicines with a primary oncology indication were also 
obtained from the European Medicines Agency’s (EMA) European public assessment reports search 
engine.6 The above criteria were used to identify new cancer medicines that were authorized by the EMA 
between 2003-2013. 
 
Drug appraisals 
Several issues made it difficult to systematically evaluate the comparative clinical benefits of new cancer 
medicines on the basis of FDA drug reviews (available within the Drugs@FDA registry). First, the FDA’s 
mandate is limited to examining whether new drugs are able to demonstrate efficacy and safety—it is not 
required to evaluate comparative therapeutic benefits, though it may do so under certain circumstances.7 
Second, the FDA’s medical and statistical reviews are also inconsistently structured, and are often 
disseminated with non-rendered text, making it difficult to systematically extract agency conclusions 
regarding the clinical benefits from drug treatment. Finally, early phase clinical trials often seek to 
“evaluate safety and identify evidence of biological drug activity, such as tumor shrinkage”, while later 
phase, confirmatory efficacy studies instead seek to “evaluate whether a drug provides a clinical benefit 
such as prolongation of survival or an improvement in symptoms.”8 Particularly in the case of medicines 
that are indicated of treatment of severe conditions with high medical need, such as cancer, FDA 
statistical and medical reviews may therefore only inconsistently contain an evaluation of drug-related 
clinical benefits that is based on late phase clinical trial evidence. At the same time, high failure rates of 
Phase III clinical trials in oncology may indicate that Phase II clinical trials alone—often used in 
 
 
 
1 US Food and Drug Administration. “Drugs@FDA: FDA Approved Drug Products.” 2015. Available from: 
https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ 
2 Roberts SA, Allen JD, Sigal E V. “Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach 
Patients Sooner In The United States Than In Europe.” Health Aff. 2011 Jul;30(7):1375–81. 
3 US Food and Drug Administration. “Drug Innovation - Novel Drug Approvals for 2011.” 2011. Center for Drug 
Evaluation and Research. Available from: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm285554.htm 
4 US Food and Drug Administration. “Drug Innovation - Novel Drug Approvals for 2012.” 2012. Center for Drug 
Evaluation and Research. Available from: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm336115.htm 
5 US Food and Drug Administration. “Drug Innovation - Novel Drug Approvals for 2013.” 2013. Center for Drug 
Evaluation and Research. Available from: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm381263.htm 6 
European Medicines Agency. “European public assessment reports.” Available from: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid= 
7 Temple R. “A regulator’s view of comparative effectiveness research.” Clin Trials. 2012;9(1):56-65. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21975523 
8 Food and Drug Administration. “Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs 
and Biologics.” 2007. Rockville, MD. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf 
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accelerated approvals—may be insufficiently informative on the effectiveness of new medicines in real- 
world settings.9 
In the absence of publicly available observational data, this analysis attempted to overcome these 
challenges by analyzing evaluations of clinical impact from cancer drug treatment from three health 
technology appraisal (HTA) agencies in England (National Institute for Health and Care Excellence, 
NICE), France (Haute Autorité de Santé, HAS) and Australia (Pharmaceutical Benefits Advisory 
Committee, PBAC), published through May 2015. These organizations are required to synthesize the 
scientific evidence to evaluate the clinical benefits of new medicines in relation to existing clinical 
standards that are used for the same indication,10,11,12 and this information is often used to then help 
regulate drug coverage, pricing, and reimbursement. Since new drug molecules are often first approved 
in the United States,2 confirmatory clinical trials are more likely to be incorporated into the reviews on 
clinical effectiveness from HTA agencies. Furthermore, these agencies operate within countries that are 
similar to the United States in terms of social and economic development, and they regularly publish 
comprehensive, and consistently structured, HTA reports in English. Though limited, the comparative 
evidence that exists appears to suggest that clinical practice guidelines for cancer treatment often 
coincide across developed healthcare settings.13,14,15 And though cancer drug molecules typically 
become available for use in the US first, they also often gain licensure in other settings.16 Where a HAS 
appraisal could not be found using the agency website’s native search engine, an additional search was 
performed for HAS reports using a general online search engine (Google) that included the drug’s active 
ingredient and “HAS Santé” (e.g. “Bortezomib HAS Santé”). In the few cases where French technological 
appraisals were not available in English, the documents were translated into English. Discussions of drug 
costs were not considered. Orphan drug status in the US and EU was obtained for each FDA-approved 
cancer drug indication from www.orpha.net. If the FDA or EMA approved two indications in its first 
evaluation of a new cancer drug (e.g. sunitinib), appraisals for both primary indications were extracted. 
 
To examine the clinical benefits from recently licensed cancer medicines, two researchers independently 
used the patient, intervention, comparator, outcomes framework to review technological appraisals that 
assessed their comparative clinical efficacy. This framework is often used in medical and health services 
 
 
 
 
 
9 Sharma MR, Stadler WM, Ratain MJ. “Randomized phase II trials: a long-term investment with promising returns.” J 
Natl Cancer Inst. 2011;103(14):1093–100. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3139588&tool=pmcentrez&rendertype=abstract 
10 National Institute for Health and Care Excellence. “NICE technology appraisal guidance.” 2016. Available from: 
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research as a structured approach to evaluate the clinical benefits from new interventions.17 Information on 
recommended patient populations (treatment indications, usage restrictions), novel interventions 
[anatomical therapeutic chemical (ATC) code, orphan status, therapeutic target] and therapeutic 
comparators were obtained from each drug appraisal. HTA agency conclusions pertaining to the overall 
survival (OS), quality of life (QoL), and safety benefits from treatment were also extracted. Methodological 
details pertaining to specific outcomes are discussed below. The data that was extracted is summarized in 
eTable 1. 
 
Overall survival 
Both reviewers identified and extracted median or mean overall survival estimates for the first approved 
indication of each newly licensed cancer drug. These were typically obtained from appraisal summary or 
conclusion sections, and were characterized by explicit value judgments of the supporting evidence, 
acknowledgement of the significance of clinical trial results, or referral to prior evaluations of the primary 
evidence. OS benefits that were given as a continuous variable were also coded as a categorical   
variable. For this, HTA documents, particularly those from NICE, frequently distinguish between OS gains 
of ≥ or <3 months over best alternative treatments.18 This rating system can be used to measure the 
likelihood of benefit from treatment: England’s HTA agency may take survival benefits of at least three 
months as “sufficient evidence to indicate that the treatment offers an extension to life.”19 England also 
uses this threshold to identify OS improvements that are large enough to justify additional expense in 
end-of-life care,20 and Australian authorities may use it to assess new health technologies.21 Besides a 
known drug-related increase in OS of greater or less than 3 months, HTA agencies may conclude that 
drugs are associated with an unquantifiable increase in overall survival, or they may be unable to make 
any conclusion on drug-related survival benefits due to a lack or insufficiency of evidence. 
 
Drugs were classified as producing an overall survival gain of ≥3 months if HTA agencies concluded that 
the drug was associated with a OS gain of ≥3 months (continuous variable), or if one-sided directional or 
range estimates fell within this space. Other possible categories of overall survival benefits included: 
known gains in OS of <3 months; an increase in survival, but of unknown magnitude; and no 
demonstrated increase in overall survival. After independent analysis, both researchers compared results 
and sought consensus if there was any disagreement in the extracted parameters. Inputs from a third 
researcher were sought where consensus could not be reached. Krippendorff’s alpha coefficient (α) were 
used to assess interagency agreement in this categorical variable reflecting HTA agency conclusions of 
overall survival benefits. This statistic should be interpreted as the percentage of the data that are coded 
to a degree better than chance.22 Krippendorff’s alpha coefficients were calculated by modelling OS 
benefits as an ordinal variable. To check for robustness, sensitivity analyses also modelled OS benefits 
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18 National Institute for Health and Care Excellence. “Value based assessment of health technologies.” 2014. 
Available  from:  https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology- 
appraisals/VBA-TA-Methods-Guide-for-Consultation.pdf 
19 National Institute for Health and Care Excellence. “Guide to the methods of technology appraisal 2013.” 2013. 
Available  from:  https://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology- 
appraisal-2013-pdf. 
20 National Institute for Health and Care Excellence. “Appraising life-extending, end of life treatments.” 2009. 
Available  from:  https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life- 
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21 Pharmaceutical Benefits Advisory Committee. Vinflunine, Solution Concentration for I.V. Infusion, 50 Mg in 2 mL 
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as a nominal variable. Krippendorff’s alpha coefficients were calculated using the krippalpha package in 
Stata 13 (College Station, TX: StataCorp LP).23 
A composite classification of overall survival benefits was developed for each drug by combining HTA 
agency appraisals. To do this, a hierarchical process was followed: if only one HTA agency evaluated a 
given drug, its assessment of gains in overall survival was taken. If drug appraisals were available from 
multiple HTA agencies, the most positive estimate of drug-related survival benefit was taken to identify   
the clinical benefits that may be possible from treatment. If no difference in overall survival could be 
established by any of the three agencies, then we classified the drug as producing no measurable change 
in overall survival. This methodology was used even if HTA agencies evaluated new medicines against a 
different set of comparators: since English, French, and Australian HTA agencies are required to evaluate 
the clinical impact of new medicines in relation to existing standards of treatment that would most likely be 
replaced by the new intervention,10,11,12 all comparator treatments were assumed to reflect possible 
courses of therapy for the given indication. 
 
Treatment standards can also change over time, giving rise to multiple comparators that should be used   
to evaluate the comparative clinical effectiveness of new medicines. To calculate the total average 
increase in overall survival between 2003-2013, the following approach was taken: if cancer drugs were 
associated with a range of values for their overall survival benefit—representing a range in the maximum 
overall survival benefit that was accepted by English, French, and Australian HTA agencies—an average 
was taken. Investigators mapped new cancer drugs against the treatment comparators that they would 
replace, as identified by HTA appraisals (Figure 2). For this, it was necessary for primary treatment 
indications to be consistent across the new intervention and the mapped comparator. Drug-specific gains 
in OS were then summed across mapped comparators to calculate the total mean gain in OS over the past 
10 years. The following are two examples of how this process was carried out: subsequent to its approval 
by the FDA in 2004 for the treatment of malignant pleural mesothelioma, pemetrexed was used                
by French and Australian HTA agencies to evaluate the clinical effectiveness of crizotinib (approved by   
the FDA in 2011 for locally advanced or metastatic non-small cell lung cancer, NSCLC). While these two 
drugs were compared against each other, the first FDA-approved indication for each of these medicines 
was not identical—the FDA eventually granted pemetrexed a licensing extension in 2006 so that it could be 
used for the same indication as crizotinib, but we did not consider non-primary indications in this study. 
Since pemetrexed and crizotinib therefore did not have an equivalent primary indication for use, their 
overall survival benefits were considered independently of each other. In contrast, erlotinib was approved 
by the FDA in 2004 for patients with locally advanced or metastatic non-small cell lung cancer and 
evaluated against placebo and BSC. Afatinib was approved by the FDA in 2013 for the same clinical 
indication, and its clinical efficacy was compared against that of erlotinib and gefitinib by HTA agencies. 
Since both afatinib and erlotinib/gefitinib were indicated for the same purpose, we compared the overall 
survival benefits associated with each medicine. Survival benefits associated with parallel treatment 
pathways (afatinib-erlotinib/gefitinib; ponatinib-nilotinib/dasatinib) were also considered independently of 
each other, as were those associated with drugs that had multiple primary indications for different 
populations (e.g. sunitinib). This exercise allowed us to map the gradual change of clinical standards over 
time, even as new drugs entered the market, and to estimate the total gain overall survival between 2003- 
2013 within and across treatment indications. Finally, gains in OS were averaged across all available 
treatments, and further stratified by therapeutic target groups (hematologicals, lung, GI, renal, breast, 
prostate, thyroid, skin, bladder, ascites, soft connective tissue). 
 
Quality of life 
Drug-related changes in QoL and toxicity were, generally, not quantified, but were instead evaluated 
qualitatively by HTA agencies. Preliminary analysis revealed that, where discussed, HTA agency 
conclusions regarding QoL could be classified into four categories: an overall improvement or reduction in 
QoL, mixed evidence, or no established difference relative to best alternative treatments. A detailed 
 
 
 
23 Staudt A, Krewel M. “krippalpha: Stata module to compute Krippendorff’s alpha intercoder reliability coefficient.” 
Available  from:  http://ideas.repec.org/c/boc/bocode/s457750.html 
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description of the QoL-related evidence that was generally considered by each HTA agency is given in 
the main text. 
 
To classify the effect on QoL from each drug, two researchers independently highlighted and analyzed all 
relevant text within appraisal summary sections. If one evaluation found there to be an improvement in 
quality of life, but a second found no change, we marked the drug as producing a net improvement in 
patient quality of life. If there were two opposing conclusions—e.g. if quality of life improved for one 
primary indication, but worsened in another—then we marked the drug as producing mixed evidence. 
Given the potential implications for clinical practice, this approach allowed us to capture the full range of 
clinical benefits to patients that may be possible from use of new cancer drugs. After independent 
analysis, both researchers compared results and sought consensus where disagreement existed. Inputs 
from a third researcher were sought where consensus could not be reached. Krippendorff’s alpha 
coefficient was used to assess interagency agreement in the magnitude of QoL benefits from new cancer 
drugs. For this, base case analyses took QoL benefits as an ordinal variable. Sensitivity analyses also 
modelled QoL benefits as a nominal variable. 
 
As for overall survival, we developed a composite QoL score from all available HTA agency assessments 
to provide an unbiased, summary measure of the expected clinical benefits from treatment. To do this, a 
procedure similar to that described above for overall survival was followed: if one HTA agency indicated 
that it believed that treatment with the new medicine improved QoL, but another found no change, we 
classified the drug as producing a net positive gain in QoL. If opposing conclusions existed—e.g. if one 
agency indicated that the drug was associated with an improvement in QoL, but another concluded that  
the drug worsened QoL—we classified the drug as producing mixed evidence. If no difference in QoL was 
established in any of the three agencies due to a lack or insufficiency of evidence, then we classified the 
drug as associated with no established change in QoL. 
 
Safety 
Summaries of the overall effect on safety from drug treatment were also extracted from HTA appraisals 
and analyzed to identify HTA agency conclusions regarding drug-related safety benefits. We did not 
consider discussion of treatment effects on the incidence of individual types of adverse events, unless the 
HTA agency explicitly stated that these were of major interest to them. Instead, our evaluations were 
based on HTA agency summary conclusions on: treatment effect on incidence of all AEs, incidence of 
serious AEs, adverse drug reactions, treatment-related AEs, treatment discontinuations or required dose 
reductions due to AEs (Table 1). Both researchers compared results after independent analysis and 
sought consensus if there was disagreement. Inputs from a third researcher were sought where  
consensus could not be reached. Krippendorff’s alpha coefficient was used to assess interagency 
agreement in the magnitude of safety benefits from cancer drug treatment. As before, base case analyses 
calculated Krippendorff’s alpha by taking safety benefits as an ordinal variable. Sensitivity analyses      
also modelled these as a nominal variable. 
 
A composite safety score was also developed to summarize drug therapeutic potential using the same 
procedure as that used to develop composite QoL scores. 
 
Overall therapeutic benefits 
To assess the overall clinical value to patients from newly developed cancer drugs, simple descriptive 
statistics were used to examine concomitant effects on OS, QoL, and safety from each drug in our 
sample. To calculate the percentage of all new cancer drugs that were associated with at least some 
evidence of overall survival, quality of life, or safety benefits, we considered the drugs that were 
associated with any evidence of improved OS (composite classification: ≥3 months, <3 months, or 
unquantifiable increase), QoL (composite classification: improvement, or mixed evidence), or safety 
(composite classification: improvement, or mixed evidence). 
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Limitations 
Surrogate measures of efficacy were not considered in this analysis, as they are not regularly measured in 
drug appraisals8 and their value to health remains unclear.24 This approach reflects the FDA’s position 
that surrogate efficacy markers are “thought to predict clinical benefit, but [are] not [themselves] a  
measure of clinical benefit”.25 Nevertheless, surrogate efficacy markers can inform clinical practice. Since 
they are not considered, this study has no bearing on the use of surrogate end points in clinical or 
regulatory practice. Improvements in efficacy were instead measured through overall survival, which is 
universally taken to indicate clinical benefit in oncology trials.26,27,28 However, if surrogate markers do in 
fact represent unique dimensions to the benefit that is derived from treatment, then their absence would 
mean that our analysis is incomplete. Surrogacy, however, implies that their value to patient health is at 
least in part captured by the three outcome measures—overall survival, quality of life, and safety—that 
are considered. 
 
To our knowledge, there is no large-scale patient-level registry on treatment and outcomes occurring prior 
to and following entry of new cancer drugs. In its absence, this study undertook a systematic process to 
review regulatory assessments and to examine the impact on therapy that would be expected from recent 
cancer drug innovations. Results from clinical trials may go unpublished, and primary clinical trial data is 
often not available for secondary analysis. HTA agencies, in contrast, may have the authority to require 
submission of all applicable clinical data,29 in theory minimizing the level of bias in their assessment. By 
drawing on these, and in the absence of observational, patient-level data, our synthesis reflects what is 
arguably the best informed analysis of the clinical impact from new drug treatments, at least at time of 
drug evaluation. Still, trial-based regulatory assessments of clinical impact may not translate to the real- 
world. To more precisely measure the clinical risks and benefits from treatment, future studies should 
extend this analysis by also incorporating post-marketing studies,30 or using observational data or 
pragmatic clinical trial evidence, as it becomes available. Future academic initiatives may be able to 
leverage data from the National Cancer Institute’s upcoming National Cancer Knowledge System—a 
component of the US Precision Medicine Initiative® that will integrate genomic information with clinical 
response data and outcomes information—to assess the real-world clinical impact from newly developed 
cancer drugs and to inform value-based supply- and demand-side decisions. 
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